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Abstract 
An efficient synthetic strategy was developed to modulate the structure of the 
tetrahydropyridine isoindolone (Valmerin) skeleton. A library of more than 30 novel final 
structures was generated. Biological activities on CDK5 and GSK3 as well as cellular effects 
on cancer cell lines were measured for each novel compound. Additionally docking studies 
were performed to support medicinal chemistry efforts. A strong GSK3/CDK5 dual inhibitor 
(38, IC50 GSK3/CDK5 32/84 nM) was obtained. A set of highly selective GSK3 inhibitors 
was synthesized by fine-tuning structural modifications (29 IC50 GSK3/CDK5 32/320 nM). 
Antiproliferative effects on cells were correlated with the in vitro kinase activities and the best 
effects were obtained with lung and colon cell lines. 
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1. Introduction 
Cancer results mainly from cell cycle perturbations and leads to anarchic cellular 
proliferation. Gene mutations associated with cancer disease induce abnormality in cellular 
proliferation and differentiation and are often linked to resistance of several therapies s [1-5]. 
The four phases  (G1, S, G2, M) are critical for the regulation of the cell cycle and.  a number 
of biochemical pathways have been discovered as key mechanisms for the initiation of a 
particular cell cycle event. Many protein kinases are activated in these biochemical pathways 
and mediate biological information in downstream signaling pathways through controlled 
phosphorylation events.  Among the 518 kinases identified to date, it has been established that 
the ubiquitously expressed glycogen synthase kinase-3 (GSK3), mainly present in the 
cytoplasm, and cyclin-depend kinase 5 (CDK5), a nuclear pivot for cell cycle progression, 
play important roles in several biological mechanisms. GSK3 and CDK5 are reported as key 
mediators in neuronal migration, embryonic development, protein synthesis, cell proliferation 
and differentiation, microtubule dynamics, cell motility, steroidogenesis and apoptosis [2]. 
Deregulation of these protein kinases has been found in many human diseases and small 
molecules kinase inhibitor, which efficiently target GSK3 and CDK5 enzymes, are considered 
as potential solutions to contain the evolution of cancer. Several drugs acting on these two 
biological targets have entered clinical trials such as roscovitine (Seliciclib) that has 
progressed to phase II (Figure 1) [6,7].  
As part of our efforts in finding better therapeutic solutions, our team has been involved 
for several years in the synthesis of novel disease-relevant kinase inhibitors and in particular 
drugs acting on CDK5, GSK3 and dual-specificity tyrosine phosphorylation-regulated kinase 
1A (DYRK1A). We have developed synthetic strategies to optimize lamellarin-like or V-
shaped indolylazines derivatives as well as oxo-arcyriaflavin or indolocarbazole analogues 
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(Figure 1), each series providing original skeletons as well as potent ATP competitive 
inhibitors able to inhibit the previously mentioned protein kinases [8].  
Figure 1. Some examples of CDK5, GSK3 and DYRK1A inhibitors.
In addition, we have also performed virtual screening campaigns on CDK5, GSK3 and 
DYRK1A to rationalise the structure-activity relationships (SAR) and to accelerate 
optimization processes. During our investigations in the proposed 
tetrahydropyridoisoindolone series, we first identified valmerin 1 (Scheme 1) and evaluated 
its biological effects. This series exhibits strong kinase inhibition, induces apoptosis in cancer 
cells and shows in vivo tumour regression. We showed that the lead compound 1 acts on 
CDK1 or CDK5 and GSK3 in the nanomolar range without any effect on DYRK1A (up to 10 
µM), the upstream regulator of CDK and GSK3.  
The development of the valmerin series, acting on GSK3 and/or CDK5, required a 
thorough exploration of each scaffold substituent to identify the critical pharmacophore. In a 
previous report, we determined that the tetrahydropyridoisoindolone core linked to a (het)Ar 
urea can induce kinase inhibition [9] and no modification to the tetrahydropyridine ring was 
explored. We surmise that such modification would interfere at the ATP binding site in the 
recognition mechanism between the novel molecules and the enzyme and would globally 
enhance the binding affinities and block kinase catalytic function. Specifically, we 
hypothesize that the structural modulation will lead to valmerins having an activity on GSK3 
and selective to CDK5 or active on both GSK3 and CDK5. Having in hand such molecules in 
a single chemical family will be useful to understand the implication of Valmerins in the CDK 
and GSK3 cell pathways. These tools will lead to a good understanding of the action mode 
and will offer to medicinal chemists solutions to prepare, as example, roscovitine successors. 
Finally, we aim to answer the following question: Is the valmerin heterocyclic scaffold a 
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promising pharmacophoric model able to modulate kinase activity with achievable cellular 
effects?  
To access the valmerin core, we modified the synthetic pathway and optimized novel 
synthetic routes. The nature and size of the urea heterocyclic group as well as the substitution 
of the tetrahydropyridine ring were the two main objectives of the chemistry efforts. The 
novel library was used to assess novel structure activity relationships. Molecular modelling 
studies were performed to corroborate the in vitro kinase activities with structural 
modifications. Finally, cellular effects were measured on several tumour cell lines in this 
study.  
Scheme 1. Retrosynthetic scheme for the design of novel CDK5, GSK3 and DYRK1A valmerin inhibitors. 
2. Chemistry 
The synthesis of valmerins was achieved from 2-nitrophtalimide 2 and led to the 
interesting nitro derivatives 3 and 4 having a protected, but not necessary, ketone on the 
tetrahydropyridine core [9]. The transformation of dioxolane to thioacetal using ethanedithiol 
in the presence of BF3.Et2O in CH2Cl2 was first performed from 3. [10] Compound 5 was 
isolated with a yield of 86%. Ketone 4 was then subjected to a reduction using sodium 
borohydride in a mixture of THF/MeOH in a 86 % yield. The separation of the two 
stereoisomers cis and trans of 4 appears as very critical. HPLC purification indicate the 
presence of a mixture of the two diastereoisomers in a 7 : 3 ratio in favor of the cis 
configuration. [11] The purification led to the an analytical amount of pure diastereoisomer 6 
in the very low yield of 14%. The next methylation step was therefore carried out on the crude 
cis+trans mixture which was isolated directly after reduction of the ketone. Fortunately only 
the cis regioisomer 6 reacted under the special conditions involving methyl iodide in the 
presence of Ag2O in THF at 50°C in a satisfying yield (other Williamson type conditions 
failed). [12] Derivative 7 was also purified satisfyingly  as a single cis diastereoisomer 
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(COSY, NOESY and HSQC NMR experiments) with a yield, calculated from 4, of 61%. 
Reduction of the nitro groups of 5 and 3 were carried out using an excess of SnCl2 and gave 
amino compounds 8 and 10 in a very good yield but, starting from 7, the reaction failed. 
When the reduction of derivative 7 was carried out under a hydrogen atmosphere, compound 
9 was generated in a 95% yield. 
Scheme 2. 
Aryl amines 8-10 were engaged in order to generate a novel valmerin series II. As kinase 
activities are directly linked to the presence of the aryl urea function, we tried several 
synthetic routes. The most convenient method remained the use of amines 8-10 which react 
from in situ freshly prepared isocyanates. Noteworthy, the previously mentioned isocyanates 
were obtained starting from the chosen carboxylic acids via a Curtius type rearrangement. 
This route appears to be very advantageous since many heteroaromatic carboxylic acids are 
commercially available. The use of this new strategy allowed us to develop an interesting 
variety of ureas 11-31 with satisfying yields. The ureas carrying an acetal were engaged in a 
final deprotection step to access the corresponding ketones. This sequence is particularly 
interesting since the direct synthesis of final derivatives, starting from 4 or 6, failed.  
Treatment of compounds 11, 14, 17, 20 and 23 with an aqueous solution of hydrochloric 
acid at 10% in refluxing acetone led to the desired ketones 32-36 with yields of up to 79%. 
The final compounds 37-41 were then directly isolated from ureas 32-36 by reduction with 
sodium borohydride in a THF/MeOH mixture. After stirring for 2 hours at a temperature 
range of 0-5 °C, the final products 37-41 were straightforwardly isolated as their single cis 
diastereoisomers, with satisfying yields. The other stereoisomer was never observed (TLC, 
1
H 
NMR of the crude material).  
Scheme 3. 
Table 1. Synthesis of Valmerins 11-41.  
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3. Kinase assays 
The library of valmerins 11-41 was first evaluated in a primary kinase screen using the 
targeted enzymes CDK5 and GSK3 and the off-target kinase DYRK1A (Table 2). In a 
previous study, we clearly showed that the urea moiety is necessary to induce a biological 
effect [9]. More specifically, close to the tetrahydropyridoisoindolone scaffold, a heteroaryl 
urea is necessary in position C-10. The heterocycles contain a nitrogen atom in position C-2’. 
Valmerin 1 acts on CDK5 and GSK3 in a quite similar manner.  
In our novel valmerins (Table 2), whatever the group used in position C-2, a urea in C-10 
with a small five-membered cycle such as pyrazole (entry 6) led to the loss of kinase 
inhibition whereas an increase in the (het)Ar size such as a quinoline moiety (entry 4) led to 
some active compounds. Derivatives 40 and 22 act mainly on GSK3 (35 and 180 nM 
respectively; entries 4e, 4c). Valmerin 40 which possesses a C-2 hydroxyl group is one of the 
most selective derivatives so far, as it interferes with CDK5 and DYRK1A in a micromolar 
range. The first discrimination of CDK5 and GSK3 is achieved in this example.  
We found CDK5 inhibitors with remarkable IC50 in the nanomolar range without effect 
on GSK3 but modifications of structures could modify the level of the second activity. When 
pyrazine was used instead of pyridine as the (het)Ar moiety, an excellent dual inhibitor was 
obtained. The inhibition values for compound 38 were 84 and 32 nM against CDK5 and 
GSK3 respectively (entry 2e). Globally each methoxylation in C-2 diminished activity and 
favored the effect on GSK3; the previously mentioned duality was lost (entries 1c-4c, 5b-7b, 
8).  
Compounds bearing a ketone in C-2 position remained inactive (entries 1d, 2d) whatever 
the tested kinase. It is possible that the presence of a planar and pi electron rich dipole was 
detrimental for kinase binding. A cyclic acetal was better tolerated by the active site despite 
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the large size of this moiety. Valmerins which possess this electron rich cycle acted 
preferentially on GSK3 (entries 1a-5a). The best score was obtained with 14, which bears the 
dioxolane ring in C-2 and inhibited GSK3 with an IC50 = 260 nM. The activity on CDK5 was 
30 fold weaker.  
Surprisingly, replacing dioxolane by dithiolane enhanced the enzymatic activities on 
GSK3 as well as on CDK5 (for derivatives 12, 15 and 27, entries 1b, 2b and 7a respectively). 
Adding a supplementary heavy lipophilic bromine atom on the pyridine urea increased 
selectivity to a very high level (entry 10). Valmerin 31 was active on GSK3 with an IC50 of 68 
nM: the selectivity toward CDK5 increased by 100 fold.  
4. Molecular modelling studies 
To rationalise the structure-activity relationships, the molecules were docked into the 
binding site of GSK3β and CDK5. We found two main modes of binding depending on the 
substituent attached to the urea moiety. In one binding mode the carboxyl group of the 
tetrahydropyridoisoindolone scaffold points towards the catalytic lysine Lys85, forming a 
hydrogen bond interaction and the urea is positioned parallel to the hinge region, creating a 
hydrogen bond interaction between the urea and the backbone of Val135 [9]. A second mode 
of binding was more frequently observed in GSK3β and is shown on Figure 2. The carboxyl 
group of the tetrahydropyridoisoindolone scaffold forms a hydrogen bond interaction with the 
NH backbone of Val35, and the urea interacts with the catalytic lysine Lys85. Interestingly, in 
this orientation the heterocyclic ring attached to the urea can form an additional hydrogen 
bond interaction with Lys85 if a nitrogen is present at the ortho position. As shown in Figure 
2, the nitrogen of the pyridine moiety from compound 29 interacts with Lys85, and a 
bidentate hydrogen bond is now present with Lys85. This binding mode can explain the 
kinase activity obtained with most of the 6-membered rings compared to 5-membered rings 
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such as pyrazole where there is a drop in kinase activity probably because of the lack of this 
hydrogen bond. 
Table 2. Kinase inhibitions of derivatives 11-41. 
The substituent attached to the saturated ring of the tetrahydropyridoisoindolone scaffold 
interacts with Thr138 through a hydrogen bond network or van der Waals interaction 
depending on the orientation of the residue side chain. Based on the binding mode analysis 
and sequence alignment of GSK3β, CDK5 and DYRK1A, we suggest that the low activity of 
the compounds for DYRK1A and CDK5 is due to the large gatekeeper residue Phe compared 
to Leu132 in GSK3β, creating a steric hindrance with the tetrahydropyridoisoindolone 
scaffold. Additionally, the lack of activity towards DYRK1A might be due to the larger 
residue Val306, compared to Ala143 and Cys199 in CDK5 and GSK3β respectively, located 
below the plane of the scaffold and at position N-1 in the DFG motif. 
Figure 2. Binding mode representation of compound 29 in GSK3β (PDB entry 1J1B).
5. Cellular screening 
The toxicity on synthesized molecules was assessed on six cancer cell lines; Huh7 (liver), 
Caco2 (colon), MDA-MB231 (breast), HCT-116 (colon), PC3 (prostate), NCI H727 (lung). 
The molecules were generally cytostatic, blocking cell cycle replication. These results are 
typical for most kinase inhibitors acting on the targeted kinases (CDK5 and GSK3β) such as 
roscovitine used in our test as a reference.  
All the derivatives which were tested on the kinase assay were evaluated on the cell line 
panel. Surprisingly all the derivatives bearing an OH in C-2 position, i.e., 38, 39 and 40, led to 
inactive derivatives as if the hydroxyl group was too sensitive and induced instability in the 
cell culture media. Among the C-2 OMe family which appears active against GSK3 (i.e., 13
and 29), only 29 led to interesting cellular effects. The best inhibition of growth was obtained 
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with the colon cell line HCT-116 (IC50 = 30 nM) and the liver cell line Huh7 (IC50 = 100 nM). 
Other cell lines were affected with an IC50 between 300 and 500 nM.  
Concerning the derivatives carrying C-2 thio acetals (12, 15, 27 and 31), cellular effects 
were maintained in the nanomolar range only when the urea (het)Ar moiety was a pyrazine 
group which could be unsubstituted or methylated (15 and 27). For compound 15, the cellular 
activity on Huh7 was similar to the one observed with 29. The toxicity against HCT-116 
remained high (IC50 = 100 nM). A real improvement on the breast cell line was observed, 
with the IC50 reaching 150 nM.  
Table 3. Most potent Valmerins in cell line assays.  
6. Conclusions 
We have developed efficient synthetic routes able to modulate the structure of the 
tetrahydropyridine skeleton. A library of more than 30 novel final structures was generated 
and our valmerin library considerably enhanced biological activities on CDK5 and GSK3. 
Cellular effects on cancer cell lines were measured for each novel compound. The proposed 
structural modifications modulated the enzyme/drug recognition mechanism. Based on this 
novel scaffold, we were able to develop inhibitors exhibiting in vitro nanomolar activities on 
either both CDK5 and GSK3 with similar potency or only GSK3 with a 100 fold activity 
factor against CDK5. Molecular modelling provided information on the interaction of the best 
candidate 29 in the GSK3 binding site. Strong interactions were developed by the creation of 
hydrogen bonds, the carbonyl having an interaction with the hinge region (NH backbone) 
whereas the 2-pyridine or pyrazine urea interacts with the catalytic lysine residue. 
Modulations of the structure led to the three best derivatives which were evaluated in cellular 
assays. Antiproliferative effects were found in the nanomolar range. The strong cytostatic 
effect induced apoptosis in several cancer cell lines and more predominantly in lung and 
colon cell lines. This novel study confirms that the valmerin heterocyclic scaffold is of 
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interest for the medicinal chemistry community and further investigations are currently in 
progress to envision a development of this series. 
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8. Experimental section. 
8.1. Chemistry. 
1
H NMR and 
13
C NMR spectra were recorded on a Bruker DPX 250 MHz or 400 
MHz instrument using CDCl3 or DMSO-d6. The chemical shifts are reported in parts per 
million ( scale) and all coupling constant (J) values are in Hertz (Hz). The following 
abbreviations were used to explain the multiplicities: s (singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet) and dd (doublet doublet). Melting points are uncorrected. IR 
absorption spectra were obtained on a Perkin Elmer PARAGON 1000 PC and values are 
reported in cm
-1
. HRMS were recorded on a Bruker maXis mass spectrometer. Monitoring 
of the reactions was performed using silica gel TLC plates (silica Merck 60 F254). Spots 
were visualized by UV light at 254 nm and 356 nm. Column chromatographies were 
performed using silica gel 60 (0.063-0.200 mm, Merck).  
8.1.1. 10-Nitro-1,3,4,10b-tetrahydro-6H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dithiolan]-
6-one 5. 
To a stirred solution of 3 (1.0 g, 3.4 mmol, 1.0 eq.) in CH2Cl2 (40 mL), were added 
dropwise, at room temperature, ethane dithiol (1.24 mL, 17.0 mmol, 5.0 eq.) and then 
BF3
.
Et2O (2.15 mL, 17.0 mmol, 5.0 eq.). After 24 h of stirring at room temperature, CH2Cl2 
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(40 mL) and an aq. NaOH (1M) solution (40 mL) were added. After extraction with CH2Cl2
(40 mL) the combined organic layers were dried over MgSO4, filtered and evaporated under 
reduced pressure. Purification by column chromatography (PE/EtOAc 40/60) led to 5 as beige 
solid in 86% yield. m.p. 185-187 °C. IR ( ATR-Diamond, cm
-1
) ν 1689, 1524, 1416, 1345, 
1079.
1
H NMR (250 MHz, CDCl3)  1.51 (dd, J = 11.2 Hz, J = 12.9 Hz, 1H), 1.97-2.19 (m, 
1H), 2.21-2.35 (m, 1H), 2.97-3.10 (m, 1H), 3.19-3.36 (m, 1H), 3.37-3.56 (m, 4H), 4.57-4.58 
(m, 1H), 5.25 (dd, J = 3.1 Hz, J = 11.2 Hz, 1H), 7.69 (t, J = 7.8 Hz, 1H), 8.18 (dd, J = 0.8 Hz, 
J = 7.8 Hz, 1H), 8.36 (dd, J = 0.8 Hz, J = 8.2 Hz, 1H). 
13
C NMR (63 MHz, CDCl3)  38.7 
(CH2), 39.3 (CH2), 39.4 (CH2), 40.7 (CH2), 45.5 (CH2), 59.5 (CH), 65.5 (Cq), 127.2 (CH), 
130.1 (CH), 130.3 (CH), 135.9 (Cq), 139.6 (Cq), 143.8 (Cq), 163.7 (Cq). HRMS (ESI) calcd. 
for C14H15N2O3S2 [M+H]
+
: 323.0524, found: 323.0509. 
8.1.2. cis-2-Hydroxy-10-nitro-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one cis-6.
To a solution of compound 4 (500 mg, 2.1 mmol, 1.0 eq.) in a THF/MeOH (10 mL/20 
mL) mixture, NaBH4 (155 mg, 4.2 mmol, 2.0 eq.) was slowly added portion wise at -20 °C. 
The solution was stirred at this temperature for 1 h and then at room temperature for 4 h. 
Water (10 mL) was added, and the aqueous phase was extracted first with CH2Cl2 (2 x 10 
mL) and then with EtOAc (10 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH 95/5) to give cis-6 as a white solid in 14% 
yield. m.p. > 260 °C. IR ( ATR-Diamond, cm
-1
) ν 2973, 1683, 1566, 1329, 1288. 
1
H NMR 
(400 MHz, DMSO-d6)  0.76 (q, J = 12.5 Hz, 1H), 1.11-1.22 (m, 1H), 1.94 (d, J = 12.5 Hz, 1H), 
2.64 (d, J = 13.2 Hz, 1H), 3.08 (td, J = 5.2 Hz, J = 12.5 Hz, 1H), 3.91-3.98 (m, 1H), 4.24 (dd, J = 
5.2 Hz, J = 12.5 Hz, 1H), 5.02-5.09 (m, 2H), 7.80 (t, J = 8.0 Hz, 1H), 8.11 (d, J = 8.0 Hz, 1H), 
8.39 (d, J = 8.0 Hz, 1H). 
13
C NMR (100 MHz, DMSO-d6)  34.0 (CH2), 36.8 (CH2), 38.4 
(CH2), 57.9 (CH), 66.4 (CH), 127.1 (CH), 129.7 (CH), 130.3 (CH), 135.1 (Cq), 139.7 (Cq), 
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143.3 (Cq), 162.6 (Cq). HRMS (ESI) calcd. for C12H13N2O4 [M+H]
+
: 249.0870, found: 
249.0871.  
8.1.3. cis-2-Methoxy-10-nitro-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one 7. 
To the solution of 6 (mixture cis and trans, 100 mg, 0.4 mmol, 1.0 eq.) in dry THF (5 
mL), were added MeI (0.25 mL, 4.0 mmol, 10.0 eq.) and freshly prepared Ag2O (37.0 mg, 1.6 
mmol, 4.0 eq.). The mixture was stirred at 50 °C for 24 h. After cooling to room temperature, 
the precipitate was filtered, washed with CH2Cl2 (3 x 10 mL) and the combined organic layers 
were concentrated in vacuum. The residue was purified by column chromatography on silica 
gel (CH2Cl2/MeOH 99/1) to afford compound 7 as a white solid in 61% yield (calcd from 4). 
m.p. 132-134 °C. IR ( ATR-Diamond, cm
-1
) ν 1688, 1523 1349, 1285, 1112, 941, 767. 1H 
NMR (400 MHz, CDCl3)  0.82 (q, J = 12.5 Hz, 1H), 1.22-1.39 (m, 1H), 2.18 (d, J = 13.2 Hz, 
1H), 2.96-3.09 (m, 2H), 3.40 (s, 3H), 3.61-3.67 (m, 1H), 4.56 (dd, J = 5.0 Hz, J = 13.2 Hz, 
1H), 4.96 (dd, J = 3.2 Hz, J = 11.6 Hz, 1H), 7.67 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 8.15 (d, J = 
7.5 Hz, 1H), 8.33 (d, J = 8.0 Hz, 1H). 
13
C NMR (100 MHz, CDCl3)  30.9 (CH2), 35.0 (CH2), 
37.3 (CH2), 56.1 (CH3), 58.6 (CH), 76.8 (CH), 127.0 (CH), 129.9 (CH), 130.1 (CH), 135.7 
(Cq), 139.6 (Cq), 143.6 (Cq), 163.5 (Cq). HRMS (ESI) calcd. for C13H15N2O4 [M+H]
+
: 
263.1026, found: 263.1030.  
8.1.4. 10-Amino-1,3,4,10b-tetrahydro-6H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]di- 
thiolan]-6-one 8. 
To a stirred solution of 5 (800 mg, 2.4 mmol) in EtOH (20 mL) was added SnCl2 (6.8 g, 
36.0 mmol, 15.0 eq.). The mixture was stirred overnight then solvent was evaporated in 
vacuum keeping the temperature of the solution below 30 °C. The residue was cooled at 0 °C 
then neutralized successively by an aqueous NaOH (2M) solution. After extraction with 
CH2Cl2 (40 mL), the combined organic layers were dried over MgSO4, filtered and evaporated 
in vacuum. The crude residue was purified by silica gel chromatography (CH2Cl2/MeOH 
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99/1) to give compound 8 as yellow solid in 80% yield. m.p. 204-206 °C. IR ( ATR-Diamond, 
cm
-1
) ν 3236, 1675, 1487, 1287, 1003. 1H NMR (250 MHz, CDCl3)  1.63-1.77 (m, 1H), 2.02 
(td, J = 5.1 Hz, J = 12.9 Hz, 1H), 2.13-2.24 (m, 1H), 2.78-2.92 (m, 1H), 3.23 (td, J = 3.2 Hz, J
= 13.3 Hz, 1H), 3.31-3.50 (m, 4H), 3.81 (br s, 2H), 4.41-4.60 (m, 2H), 6.80 (dd, J = 1.3 Hz, J
= 7.2 Hz, 1H), 7.17-7.37 (m, 2H). 
13
C NMR (63 MHz, CDCl3)  38.4 (CH2), 38.7 (CH2), 39.7 
(CH2), 41.6 (CH2), 45.7 (CH2), 57.1 (CH), 65.7 (Cq), 114.3 (CH), 118.4 (CH), 129.0 (Cq), 
129.7 (CH), 133.3 (Cq), 141.4 (Cq), 166.7 (Cq). HRMS (ESI) calcd. for 
C14H17N2OS2 [M+H]
+
: 293.0782, found: 293.0774. 
8.1.5. cis-10-Amino-2-methoxy-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one 9. 
To a stirred solution of compound 7 (1.0 g, 3.8 mmol) in absolute EtOH (30 mL) was 
added freshly prepared W Raney Nikel (ca 200 mg). The resulting suspension was 
hydrogenated (1 atm) at room temperature for 14 h. The mixture was filtered through a pad of 
celite and washed with CH2Cl2 (3 x 10 mL). The combined organic layers were concentrated 
under vacuum to give compound 9 as a yellow solid in 95% yield. m.p. 60-62 °C. IR ( ATR-
Diamond, cm
-1
) ν 3236, 1683, 1566, 1288. 1H NMR (250 MHz, CDCl3)  1.05 (q, J = 12.2 
Hz, 1H), 1.34-1.41 (m, 1H), 2.18 (d, J = 12.2 Hz, 1H), 2.80 (d, J = 12.2 Hz, 1H), 2.96 (td, J = 
2.5 Hz, J = 12.0 Hz, 1H), 3.40 (s, 3H), 3.52-3.62 (m, 1H), 3.82 (br s, 2H), 4.30 (dd, J = 5.0 
Hz, J = 12.0 Hz, 1H), 4.54 (dd, J = 5.0 Hz, J = 11.7 Hz, 1H), 6.80 (d, J = 8.5 Hz, 1H), 7.25 
(m, 2H). 
13
C NMR (63 MHz, CDCl3)  30.9 (CH2), 35.5 (CH2), 37.0 (CH2), 55.9 (CH3), 56.2 
(CH), 77.1 (CH), 114.2 (CH), 118.3 (CH), 129.0 (Cq), 129.4 (CH), 133.2 (Cq), 141.2 (Cq), 
166.6 (Cq). HRMS (ESI) calcd. for C13H17N2O2 [M+H]
+
: 233.1285, found: 233.1289. 
8.1.6. 10-Amino-1,3,4,10b-tetrahydro-6H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3] 
dioxolan]-6-one 10. 
Derivative 10 was prepared from 3 as previously described for 8. The crude residue was 
purified by silica gel chromatography (CH2Cl2/MeOH 99/1) to give compound 10 as a white 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
solid in 82% yield. m.p. 76-78 °C. IR ( ATR-Diamond, cm
-1
) ν 1710, 1542, 1366, 1143, 1028. 
1
H NMR (250 MHz, CDCl3)  1.38 (t, J = 12.5 Hz, 1H), 1.67 (td, J = 5.7 Hz, J = 13.0 Hz, 
1H), 1.81-1.83 (m, 1H), 2.44-2.46 (m, 1H), 3.23 (td, J = 3.9 Hz, J = 13.0 Hz, 1H), 3.74 (br s, 
2H), 3.99-4.14 (m, 4H), 4.41-4.61 (m, 2H), 6.81 (dd, J = 1.8 Hz, J = 7.0 Hz, 1H), 7.24-7.36 
(m, 2H). 
13
C NMR (63 MHz, CDCl3)  34.1 (CH2), 36.6 (CH2), 39.1 (CH2), 55.8 (CH), 64.9 
(CH2), 65.1 (CH2), 107.7 (Cq), 114.5 (CH), 118.4 (CH), 129.5 (Cq), 129.6 (CH), 133.5 (Cq), 
141.2 (Cq), 166.8 (Cq). HRMS (ESI) calc. for C14H17N2O3 [M+H]
+
: 261.1239, found: 
261.1238. 
8.1.7. General procedure A for the urea synthesis. 
Under Argon, a stirred solution of carboxylic acid (0.37 mmol, 1.0 eq.) and Et3N (0.48 
mmol, 1.3 eq.) in dry THF (7 mL) was cooled to -10 °C. Ethyl chloroformate (0.55 mmol, 1.5 
eq.) was dropwise added and the resulting mixture was stirred for 2 h. Afterwards, a solution 
of sodium azide (0.63 mmol, 1.7 eq.) in water (2 mL) was added in one portion. After 1 h at -
10 °C, the reaction was found to be complete (TLC) and was quenched into iced water (5 
mL). The mixture was extracted with EtOAc (3 x 10 mL) and the combined organic layers 
were successively dried over MgSO4, filtered and evaporated. The crude acyl azide was 
placed in dry toluene (20 mL) and heated at reflux for 1 h to give the corresponding crude 
isocyanate. The latter was placed in dry dioxane (7 mL) prior to adding the appropriate amine 
8, 9 or 10 (0.37 mmol, 1.0 eq.). The solution was heated at 100 °C for 24 h. The reaction 
mixture was cooled and the volatiles were removed to dryness in vacuum at 40 °C.  
8.1.8. 1-(6-Oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dioxolan]-
10-yl)-3-(pyridin-2-yl)urea 11. 
Compound 11 was obtained following the general procedure A from the amine 10 and 
pyridin-2-carboxylic acid after purification by flash chromatography (CH2Cl2/MeOH 99 /1) as 
a white solid in 78% yield. m.p. 178-180 °C. IR ( ATR-Diamond, cm
-1
) ν 3305-3224, 1651, 
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1529- 1485-1427, 1288, 1200, 723.
1
H NMR (400 MHz, DMSO-d6)  1.27 (t, J = 12.3 Hz, 
1H), 1.50 (td, J = 5.7 Hz, J = 13.1, 1H), 1.85 (d, J = 13.1 Hz, 1H), 2.62 (dd, J = 2.1 Hz, J = 
9.3 Hz, 1H), 3.16 (td, J = 3.4 Hz, J = 13.1 Hz, 1H), 3.85 (dd, J = 6.3 Hz, J = 14.1 Hz, 1H), 
3.96 (dt, J = 6.3 Hz, J = 12.3 Hz, 1H), 4.01-4.09 (m, 2H), 4.29 (dd, J = 4.7 Hz, J = 13.1 Hz, 
1H), 4.81 (dd, J = 3.4 Hz, J = 12.3 Hz, 1H), 7.09 (dd, J = 5.5 Hz, J = 6.8 Hz, 1H), 7.26 (d, J = 
8.3 Hz, 1H), 7.36-7.43 (m, 1H), 7.47 (t, J = 7.7 Hz, 1H), 7.74-7.86 (m, 1H), 8.21-8.35 (m, 
2H), 9.95 (s, 1H), 11.42 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  33.0 (CH2), 36.1 (CH2), 
38.3 (CH2), 55.5 (CH), 64.0 (CH2), 64.3 (CH2), 106.8 (Cq), 112.1 (CH), 117.5 (CH), 117.6 
(CH), 122.5 (CH), 129.1 (CH), 132.7 (Cq), 133.9 (Cq), 134.2 (Cq), 139.1 (CH), 146.0 (CH), 
152.1 (Cq), 152.9 (Cq), 164.8 (Cq). HRMS (ESI) calc. for C20H21N4O4 [M+H]
+
: 381.1563, 
found: 381.1553. 
8.1.9. 1-(6-Oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dithiolan]-
10-yl)-3-(pyridin-2-yl)urea 12. 
Compound 12 was obtained following the general procedure A from the amine 8 and 
pyridin-2-carboxylic acid after purification by flash chromatography (CH2Cl2/MeOH 99 /1) as 
a white solid in a 96% yield. m.p. 242-244 °C. IR ( ATR-Diamond, cm
-1
) ν  1703, 1677, 
1553, 1510, 1483, 1418, 1310, 1153.
1
H NMR (400 MHz, DMSO-d6)  1.22-1.37 (m, 1H), 
1.75 (t, J = 11.3 Hz, 1H), 1.92 (d, J = 13.3 Hz, 1H), 2.72 (dd, J = 2.6 Hz, J = 12.6 Hz, 1H), 
2.97-3.14 (m, 1H), 3.23-3.52 (m, 4H), 4.27 (dd, J = 4.4 Hz, J = 13.0 Hz, 1H), 4.59 (dd, J = 
3.3 Hz, J = 11.5 Hz, 1H), 7.03-7.12 (m, 1H), 7.34 (d, J = 8.3 Hz, 1H), 7.39 (dd, J = 0.8 Hz, J
= 7.4 Hz, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.75-7.86 (m, 1H), 8.23 (d, J = 7.9 Hz, 1H), 8.26-8.33 
(m, 1H), 10.00 (s, 1H), 11.17 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  37.7 (CH2), 38.2 
(CH2), 38.9 (CH2), 40.7 (CH2), 44.1 (CH2), 56.9 (CH), 65.6 (Cq), 112.1 (CH), 117.4 (CH), 
117.8 (CH), 123.6 (CH), 129.1 (CH), 132.7 (Cq), 133.8 (Cq), 134.1 (Cq), 139.1 (CH), 146.4 
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(CH), 152.2 (Cq), 152.9 (Cq), 164.8 (Cq). HRMS (ESI) calc. for C20H20N4O2S2Na [M+Na]
+
: 
435.0878, found: 435.0870. 
8.1.10. cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-
(pyridin-2-yl)urea 13. 
Compound 13 was prepared following the general procedure A from the amine 9 and 
pyridin-2-carboxylic acid after purification by flash chromatography (CH2Cl2/MeOH 99 /1) as 
a yellow solid in 81% yield. m.p. 166-168 °C. IR ( ATR-Diamond, cm
-1
) ν  1688, 1602, 1579, 
1478, 1418, 1312, 1291, 751. 
1
H NMR (400 MHz, CDCl3)  1.04 (q, J = 12.5 Hz, 1H), 1.13-
1.42 (m, 1H), 2.21 (d, J = 12.5 Hz, 1H), 3.01-3.09 (m, 2H), 3.37 (s, 3H), 3.59-3.65 (m, 1H), 
4.60 (dd, J = 3.2 Hz, J = 12.5 Hz, 2H), 6.90 (d, J = 8.0 Hz, 1H), 7.01 (dd, J = 7.5 Hz, J = 8.0 
Hz, 1H), 7.49 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.70 (td, J = 7.5 Hz, J
= 8.0 Hz, 1H), 8.15 (d, J = 8.0 Hz, 1H), 8.26 (d, J = 4.0 Hz, 1H), 8.66 (s, 1H), 11.98 (s, 1H). 
13
C NMR (100 MHz, CDCl3)  30.7 (CH2), 35.6 (CH2), 37.1 (CH2), 55.9 (CH3), 57.0 (CH), 
77.4 (CH), 112.4 (CH), 117.7 (CH), 119.5 (CH), 124.5 (CH), 129.4 (CH), 133.2 (Cq), 133.3 
(Cq), 135.0 (Cq), 139.2 (CH), 145.5 (CH), 152.7 (Cq), 153.3 (Cq), 166.0 (Cq). HRMS (ESI) 
calc. for C19H21N4O3 [M+H]
+
: 353.1614, found: 353.1603. 
8.1.11. 1-(6-Oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dioxolan] 
-10-yl)-3-(pyrazin-2-yl)urea 14. 
Compound 14 was obtained following the general procedure A from the amine 10 and 
pyrazin-2-carboxylic acid after purification by flash chromatography (CH2Cl2/MeOH 99/1) as 
a pale brown solid in 68% yield. m.p. > 260 °C. IR ( ATR-Diamond, cm
-1
) ν  1698, 1570, 
1549-1504-1478, 1298, 1244, 1073. 
1
H NMR (400 MHz, DMSO-d6)  1.23 (t, J = 12.3 Hz, 
1H), 1.51 (td, J = 5.7 Hz, J = 13.1 Hz, 1H), 1.83 (d, J = 13.1 Hz, 1H), 2.55 (d, J = 11.5 Hz, 
1H), 3.15 (td, J = 4.0 Hz, J = 13.1 Hz, 1H), 3.83-4.00 (m, 2H), 4.01-4.14 (m, 2H), 4.28 (dd, J
= 4.0 Hz, J = 13.3 Hz, 1H), 4.78 (dd, J = 3.6 Hz, J = 12.0 Hz, 1H), 7.43 (d, J = 6.9 Hz, 1H), 
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7.49 (t, J = 7.8 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 8.25-8.34 (m, 2H), 8.88 (s, 1H), 10.03 (s, 
1H), 10.12 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  33.1 (CH2), 36.1 (CH2), 38.1 (CH2), 
55.5 (CH), 64.0 (CH2), 64.3 (CH2), 106.8 (Cq), 118.0 (CH), 123.3 (CH), 129.1 (CH), 132.8 
(Cq), 133.5 (Cq), 134.8 (Cq), 135.5 (CH), 137.8 (CH), 140.8 (CH), 149.2 (Cq), 151.7 (Cq), 
164.7 (Cq). HRMS (ESI) calc. for C19H19N5O4Na [M+Na]
+
: 404.1335, found: 404.1327. 
8.1.12. 1-(6-Oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dithiolan 
]-10-yl)-3-(pyrazin-2-yl)urea 15. 
Compound 15 was obtained following the general procedure A from the amine 8 and 
pyrazin-2-carboxylic acid after purification by flash chromatography (CH2Cl2/MeOH 99 /1) 
as a white solid in 90% yield. m.p. 236-238 °C. IR ( ATR-Diamond, cm
-1
) ν  1676, 1551, 
1505-1483-1421, 1298, 1138.
1
H NMR (400 MHz, DMSO-d6)  1.63 (t, J = 12.3 Hz, 1H), 
1.96 (td, J = 5.0 Hz, J = 12.3 Hz, 1H), 2.14 (d, J = 13.2 Hz, 1H), 2.89 (d, J = 11.5 Hz, 1H), 
3.16 (td, J = 3.1 Hz, J = 13.3 Hz, 1H), 3.28-3.48 (m, 4H), 4.33 (dd, J = 3.1 Hz, J = 13.3 Hz, 
1H), 4.79 (dd, J = 3.1 Hz, J = 11.5 Hz, 1H), 7.42-7.54 (m, 2H), 8.08 (dd, J = 0.9 Hz, J = 7.8 
Hz, 1H), 8.29 (d, J = 2.7 Hz, 1H), 8.40 (dd, J = 1.5 Hz, J = 2.6 Hz, 1H), 8.83 (d, J = 1.1 Hz, 
1H), 10.13 (s, 1H), 10.19 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  37.7 (CH2), 38.2 (CH2), 
38.7 (CH2), 40.5 (CH2), 44.0 (CH2), 56.9 (CH), 65.6 (Cq), 118.3 (CH), 124.1 (CH), 129.1 
(CH), 132.8 (Cq), 133.4 (Cq), 134.7 (Cq), 135.6 (CH), 137.7 (CH), 140.8 (CH), 149.2 (Cq), 
151.7 (Cq), 164.7 (Cq). HRMS (ESI) calc. for C19H19N5O2S2Na [M+Na]
+
: 436.0878, found: 
436.0870. 
8.1.13. cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-
(pyrazin-2-yl)urea 16. 
Compound 16 was prepared following the general procedure A from the amine 9 and 
pyrazin-2-carboxylic acid after purification by flash chromatography (CH2Cl2/MeOH 99/1) as 
a yellow solid in 78% yield. m.p. 192-194 °C. IR ( ATR-Diamond, cm
-1
) ν  1684, 1595, 1557, 
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1486, 1421, 1306, 1084, 753. 
1
H NMR (400 MHz, DMSO-d6)  0.80 (q, J = 12.5 Hz, 1H), 
1.14-1.24 (m, 1H), 2.19 (d, J = 12.5 Hz, 1H), 2.97 (d, J = 13.5 Hz, 1H), 3.14 (td, J = 3.2 Hz, J
= 12.5 Hz, 1H), 3.28 (s, 3H), 3.69-3.77 (m, 1H), 4.34 (dd, J = 4.0 Hz, J = 13.5 Hz, 1H), 4.73 
(dd, J = 3.2 Hz, J = 13.5 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.54 (dd, J = 7.8 Hz, J = 8.0 Hz, 
1H), 8.20 (d, J = 8.0 Hz, 1H), 8.35 (d, J = 3.2 Hz, 1H), 8.40 (dd, J = 1.6 Hz, J = 3.2 Hz, 1H), 
9.00 (d, J = 1.6 Hz, 1H), 9.85 (s, 1H), 10.14 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  30.7 
(CH2), 35.3 (CH2), 36.4 (CH2), 55.2 (CH3), 55.8 (CH), 76.3 (CH), 118.0 (CH), 123.1 (CH), 
129.1 (CH), 132.8 (Cq), 133.5 (Cq), 134.5 (Cq), 135.5 (CH), 137.9 (CH), 141.1 (CH), 149.2 
(Cq), 151.7 (Cq), 164.6 (Cq). HRMS (ESI) calc. for C18H19N5O3Na [M+Na]
+
: 376.1386, 
found: 376.1370. 
8.1.14. 1-(6-Methylpyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a] 
isoindole-2,2'-[1,3]dioxolan]-10-yl)urea 17. 
Compound 17 was prepared following the general procedure A from the amine 10 and 
6-methylpicolinic acid after purification by flash chromatography (CH2Cl2/MeOH 99/1) as a 
white solid in 75% yield. m.p. 240-242 °C. IR ( ATR-Diamond, cm
-1
) ν  3180, 1685, 1584, 
1560, 1510, 1327, 1287, 751.
1
H NMR (400 MHz, CDCl3)  1.33 (t, J = 12.5 Hz, 1H), 1.69 
(td, J = 5.0 Hz, J = 12.5 Hz, 1H), 1.80 (d, J = 12.5 Hz, 1H), 2.53 (d, J = 13.5 Hz, 1H), 2.60 (s, 
3H), 3.27 (td, J = 2.5 Hz, J = 13.5 Hz, 1H), 3.74-4.05 (m, 4H), 4.53 (dd, J = 5.0 Hz, J = 12.5 
Hz, 1H), 4.93 (dd, J = 2.5 Hz, J = 12.5 Hz, 1H), 6.73 (d, J = 7.5 Hz, 1H), 6.82 (d, J = 7.5 Hz, 
1H), 7.47-7.59 (m, 2H), 7.67 (d, J = 7.5 Hz, 1H), 7.99 (d, J = 7.5 Hz, 1H), 9.16 (s, 1H), 12.14 
(s, 1H). 
13
C NMR (100 MHz, CDCl3)  22.8 (CH3), 33.0 (CH2), 35.5 (CH2), 37.2 (CH2), 55.5 
(CH), 63.5 (CH2), 63.6 (CH2), 106.4 (Cq), 108.3 (CH), 115.7 (CH), 118.7 (CH), 124.9 (CH), 
128.1 (CH), 131.8 (Cq), 132.3 (Cq), 135.1 (Cq), 138.2 (CH), 151.4 (Cq), 152.9 (Cq), 154.4 
(Cq), 165.1 (Cq). HRMS (ESI) calc. for C21H23N4O4 [M+H]
+
: 395.1719, found: 395.1733. 
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8.1.15. 1-(6-Methylpyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a] 
isoindole-2,2'-[1,3]dithiolan]-10-yl)urea 18. 
Compound 18 was prepared following the general procedure A from the amine 8 and 6-
methylpicolinic acid after purification by flash chromatography (CH2Cl2/MeOH 99/1) as a 
white solid in 78% yield. m.p. 154-156 °C. IR ( ATR-Diamond, cm
-1
) ν  2922, 1689, 1622, 
1596, 1429, 1355, 1290, 741.
1
H NMR (400 MHz, CDCl3)  1.61 (t, J = 12.5 Hz, 1H), 2.03 
(td, J = 5.0 Hz, J = 12.5 Hz, 1H), 2.18 (d, J = 12.5 Hz, 1H), 2.60 (s, 3H), 2.89 (d, J = 13.5 Hz, 
1H), 3.14-3.29 (m, 5H), 4.53 (dd, J = 2.5 Hz, J = 13.5 Hz, 1H), 4.92 (dd, J = 2.5 Hz, J = 13.5 
Hz, 1H), 6.83 (d, J = 8.0 Hz, 2H), 7.47 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.58-7.65 (m, 1H), 
7.68 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 9.48 (s, 1H), 12.05 (s, 1H). 
13
C NMR (100 
MHz, CDCl3)  29.3 (CH3), 38.3 (CH2), 38.6 (CH2), 38.8 (CH2), 40.5 (CH2), 45.1 (CH2), 57.8 
(CH), 65.5 (Cq), 109.8 (CH), 116.8 (CH), 120.4 (CH), 127.0 (CH), 129.1 (2 CH), 132.4 (Cq), 
133.4 (Cq), 136.8 (2 Cq), 152.1 (Cq), 154.0 (Cq), 165.8 (Cq). HRMS (ESI) calc. for 
C21H23N4O2S2 [M+H]
+
: 427.1262, found: 427.1278. 
8.1.16. cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(6-
methyl-pyridin-2-yl)urea 19. 
Compound 19 was prepared from following the general procedure A from the amine 9
and 6-methylpicolinic acid after purification by flash chromatography (CH2Cl2/MeOH 99 /1) 
as a white solid in 75% yield. m.p. 167-169 °C. IR ( ATR-Diamond, cm
-1
) ν  1689, 1589, 
1556, 1436, 1283, 751. 
1
H NMR (400 MHz, CDCl3)  1.03 (q, J = 12.5 Hz, 1H), 1.27-1.38 
(m, 1H), 2.19 (d, J = 12.5 Hz, 1H), 2.56 (s, 3H), 2.93 (d, J = 12.5 Hz, 1H), 3.02 (td, J = 3.2 
Hz, J = 13.5 Hz, 1H), 3.30 (s, 3H), 3.53-3.59 (m, 1H), 4.58 (dd, J = 4.5 Hz, J = 13.5 Hz, 1H), 
4.69 (dd, J = 3.2 Hz, J = 12.5 Hz, 1H), 6.70 (d, J = 8.0 Hz, 1H), 6.83 (d, J = 7.5 Hz, 1H), 7.49 
(dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.55 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.66 (d, J = 8.0 Hz, 
1H), 7.99 (d, J = 8.0 Hz, 1H), 8.93 (s, 1H), 11.98 (s, 1H). 
13
C NMR (100 MHz, CDCl3)  24.4 
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(CH3), 30.6 (CH2), 35.1 (CH2), 37.1 (CH2), 55.8 (CH3), 57.2 (CH), 77.3 (CH), 109.4 (CH), 
117.0 (CH), 120.0 (CH), 125.8 (CH), 129.2 (CH), 133.0 (Cq), 133.4 (Cq), 135.8 (Cq), 139.2 
(CH), 152.3 (Cq), 153.7 (Cq), 155.0 (Cq), 166.0 (Cq). HRMS (ESI) calc. for C20H23N4O3 
[M+H]
+
: 367.1770, found: 367.1776. 
8.1.17. 1-(4-Methoxyquinolin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a] 
isoindole-2,2'-[1,3]dioxolan]-10-yl)urea 20. 
Compound 20 was prepared following the general procedure A from the amine 10 and 
4-methoxyquinoline-2-carboxylic acid after purification by flash chromatography 
(CH2Cl2/MeOH 99/1) as a yellow solid in 72% yield. m.p. 258-260 °C. IR ( ATR-Diamond, 
cm
-1
) ν  2967, 1689, 1621, 1585, 1414, 1332, 1289, 751 . 1H NMR (400 MHz, CDCl3)  1.38 
(t, J = 12.5 Hz, 1H), 1.62-1.81 (m, 2H), 2.72 (d, J = 13.5 Hz, 1H), 3.27-3.39 (m, 2H), 3.59-
3.77 (m, 3H), 4.02 (s, 3H), 4.56 (dd, J = 2.5 Hz, J = 13.5 Hz, 1H), 5.01 (dd, J = 2.5 Hz, J = 
13.5 Hz, 1H), 6.47 (s, 1H), 7.38-7.49 (m, 2H), 7.67-7.73 (m, 2H), 7.95 (d, J = 7.5 Hz, 1H), 
8.10 (d, J = 7.5 Hz, 1H), 8.23 (d, J = 7.5 Hz, 1H), 9.86 (s, 1H), 12.57 (s, 1H). 
13
C NMR (100 
MHz, CDCl3)  34.1 (CH2), 36.6 (CH2), 38.3 (CH2), 55.8 (CH3), 56.5 (CH), 64.5 (CH2), 64.6 
(CH2), 91.5 (CH), 107.2 (Cq), 118.8 (Cq), 119.6 (CH), 121.9 (CH), 124.2 (CH), 125.3 (CH), 
126.5 (CH), 128.8 (CH), 130.5 (CH), 133.0 (Cq), 133.3 (Cq), 135.7 (Cq), 145.9 (Cq), 153.4 
(Cq), 154.4 (Cq), 163.9 (Cq), 166.1 (Cq). HRMS (ESI) calc. for C25H25N4O5 [M+H]
+
: 
461.1825, found: 461.1844. 
8.1.18. 1-(4-Methoxyquinolin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a] 
isoindole-2,2'-[1,3]dithiolan]-10-yl)urea 21. 
Compound 21 was prepared following the general procedure A from the amine 8 and 4-
methoxyquinoline-2-carboxylic acid after purification by flash chromatography 
(CH2Cl2/MeOH 99/1) as a yellow solid in 80% yield. m.p. 250-252 °C. IR ( ATR-Diamond, 
cm
-1
) ν  2975, 1685, 1621, 1585, 1414, 1332, 1289, 751. 1 H NMR (400 MHz, CDCl3)  1.68 
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(t, J = 12.5 Hz, 1H), 2.06 (td, J = 5.0 Hz, J = 12.5 Hz, 1H), 2.19 (d, J = 12.5 Hz, 1H), 2.47-
2.57 (m, 1H), 2.78-3.13 (m, 4H), 3.19 (td, J = 5.0 Hz, J = 13.5 Hz, 1H), 4.00 (s, 3H), 4.58 (dd,
J = 2.5 Hz, J = 13.5 Hz, 1H), 5.07 (dd, J = 2.5 Hz, J = 12.5 Hz, 1H), 6.48 (s, 1H), 7.39 (dd, J
= 7.5 Hz, J = 8.0 Hz, 1H), 7.49 (d, J = 7.5 Hz, 1H), 7.64 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.72 
(d, J = 7.5 Hz, 1H), 8.00 (dd, J = 7.5 Hz, J = 8.0 Hz, 2H), 8.08 (d, J = 7.5 Hz, 1H), 10.01 (s, 
1H), 12.56 (s, 1H). 
13
C NMR (100 MHz, CDCl3)  38.2 (CH2), 38.3 (CH2), 39.0 (CH2), 40.2 
(CH2), 45.4 (CH2), 55.8 (CH3), 57.7 (CH), 65.3 (Cq), 91.5 (CH), 118.7 (Cq), 120.2 (CH), 
121.8 (CH), 124.2 (CH), 126.8 (CH), 127.0 (CH), 128.7 (CH), 130.4 (CH), 132.7 (Cq), 133.4 
(Cq), 136.4 (Cq), 145.8 (Cq), 153.4 (Cq), 154.6 (Cq), 163.9 (Cq), 165.9 (Cq). HRMS (ESI) 
calc. for C25H25N4O3S2 [M+H]
+
: 493.1368, found: 493.1384. 
8.1.19. cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-
methoxyquinolin-2-yl)urea 22. 
Compound 22 was prepared following the general procedure A from the amine 9 and 4-
methoxyquinoline-2-carboxylic acid after purification by flash chromatography 
(CH2Cl2/MeOH 99/1) as a white solid in 80% yield. m.p. > 260 °C. IR ( ATR-Diamond, cm
-1
) 
ν  1694, 1610, 1556, 1479, 1416, 1338, 1295, 759. 1H NMR (400 MHz, DMSO-d6)  0.76 (q, 
J = 12.5 Hz, 1H), 1.05-1.15 (m, 1H), 2.09 (d, J = 12.5 Hz, 1H), 2.82 (s, 3H), 2.91 (d, J = 13.5 
Hz, 1H), 3.15 (td, J = 3.2 Hz, J = 13.5 Hz, 1H), 3.59 (d, J = 12.0 Hz, 1H), 4.01 (s, 3H), 4.30 
(dd, J = 4.0 Hz, J = 13.5 Hz, 1H), 4.92 (dd, J = 3.2 Hz, J = 12.0 Hz, 1H), 6.84 (s, 1H), 7.41-
7.51 (m, 3H), 7.77 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 8.0 
Hz, 1H), 8.29 (d, J = 8.0 Hz, 1H), 10.15 (s, 1H), 11.99 (s, 1H). 
13
C NMR (100 MHz, DMSO-
d6)  30.8 (CH2), 34.4 (CH2), 36.4 (CH2), 54.7 (CH3), 55.9 (CH), 56.0 (CH3), 76.4 (CH), 91.9 
(CH), 117.8 (CH), 118.1 (Cq), 121.5 (CH), 123.6 (CH), 124.1 (CH), 126.3 (CH), 128.9 (CH), 
130.7 (CH), 132.8 (Cq), 133.7 (Cq), 134.3 (Cq), 145.6 (Cq), 152.3 (Cq), 153.8 (Cq), 162.9 
(Cq), 164.6 (Cq). HRMS (ESI) calc. for C24H25N4O4 [M+H]
+
: 433.1876, found: 433.1884. 
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8.1.20. 1-(3-Methylpyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a] 
isoindole-2,2'-[1,3]dioxolan]-10-yl)urea 23.
Compound 23 was prepared following the general procedure A from the amine 10 and 
3-methylpicolinic acid after purification by flash chromatography (CH2Cl2/MeOH 99/1) as a 
white solid in 72% yield. m.p. > 260 °C. IR ( ATR-Diamond, cm
-1
) ν  1679, 1566, 1480-1415, 
1291, 1135.
1
H NMR (400 MHz, DMSO-d6)  1.35 (t, J = 12.5 Hz, 1H), 1.53 (td, J = 5.0 Hz, 
J = 12.5 Hz, 1H), 1.86 (d, J = 12.5 Hz, 1H), 2.32 (s, 3H), 2.62 (d, J = 12.5 Hz, 1H), 3.17 (td, J
= 3.2 Hz, J = 13.5 Hz, 1H), 3.81-4.07 (m, 4H), 4.30 (dd, J = 3.2 Hz, J = 13.5 Hz, 1H), 4.84 
(dd, J = 3.3 Hz, J = 12.5 Hz, 1H), 7.09 (dd, J = 7.0 Hz, J = 8.0 Hz, 1H), 7.39-7.50 (m, 2H), 
7.69 (d, J = 7.0 Hz, 1H), 8.23 (d, J = 7.5 Hz, 1H), 8.33 (d, J = 7.5 Hz, 1H), 8.85 (s, 1H), 12.4 
(s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  17.5 (CH3) 34.4 (CH2), 36.4 (CH2), 37.8 (CH2), 
55.7 (CH), 64.3 (CH2), 64.6 (CH2), 107.4 (Cq), 110.8 (CH), 112.7 (CH), 117.5 (CH), 129.2 
(CH), 133.0 (Cq), 134.6 (Cq), 137.2 (CH), 143.3 (Cq), 143.9 (Cq), 145.5 (CH), 151.6 (Cq), 
152.7 (Cq), 166.2 (Cq). HRMS (ESI) calc. for C21H23N4O4 [M+H]
+
: 395.1719, found: 
395.1731. 
8.1.21. cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(3-
methylpyridin-2-yl)urea 24. 
Compound 24 was prepared following the general procedure A from the amine 9 and 3-
methylpicolinic acid after purification by flash chromatography (CH2Cl2/MeOH 99/1) as a 
yellow solid in 73% yield. m.p. 222-224 °C. IR ( ATR-Diamond, cm
-1
) ν  1692, 1592, 1554, 
1484, 1421, 1298, 1189, 751. 
1
H NMR (400 MHz, CDCl3)  1.02 (q, J = 12.5 Hz, 1H), 1.30-
1.40 (m, 1H), 2.20 (d, J = 12.5 Hz, 1H), 2.31 (s, 3H), 3.03 (td, J = 3.2 Hz, J = 12.5 Hz, 2H), 
3.36 (s, 3H), 3.60-3.65 (m, 1H), 4.58 (dd, J = 3.2 Hz, J = 12.0 Hz, 2H), 6.95 (dd, J = 7.5 Hz, J
= 8.0 Hz, 1H), 7.11 (s, 1H), 7.46 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.53 (d, J = 7.5 Hz, 1H), 
7.61 (d, J = 7.5 Hz, 1H), 8.13-8.16 (m, 2H), 12.24 (s, 1H). 
13
C NMR (100 MHz, CDCl3) 
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17.1 (CH3), 30.9 (CH2), 35.7 (CH2), 37.2 (CH2), 56.1 (CH3), 57.1 (CH), 77.6 (CH), 117.9 
(CH), 119.6 (CH), 119.7 (Cq), 124.6 (CH), 129.5 (CH), 133.2 (Cq), 133.3 (Cq), 135.0 (Cq), 
139.9 (CH), 143.2 (CH), 151.2 (Cq), 152.7 (Cq), 166.2 (Cq). HRMS (ESI) calc. for 
C20H23N4O3 [M+H]
+
: 367.1770, found: 367.1778. 
8.1.22. 1-(1-methyl-1H-pyrazol-3-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido [2,1-
a]isoindole-2,2'-[1,3]dithiolan]-10-yl)urea 25. 
Compound 25 was obtained following the general procedure A from the amine 8 and 1-
methyl-1H-pyrazole-3-carboxylic acid after purification by flash chromatography 
(CH2Cl2/MeOH 99/1) as a yellow solid in 68% yield. m.p. 134-136 °C. IR ( ATR-Diamond, 
cm
-1
) ν  3256, 2923, 1676, 1530, 1485, 1287. 1H NMR (400 MHz, CDCl3)  1.62 (t, J = 12.5 
Hz, 1H), 2.01 (td, J = 5.0 Hz, J = 12.5 Hz, 1H), 2.17 (d, J = 12.5 Hz, 1H), 2.95 (d, J = 13.5 
Hz, 1H), 3.16-3.33 (m, 5H), 3.87 (s, 3H), 4.52 (dd, J = 3.8 Hz, J = 13.5 Hz, 1H), 4.81 (dd, J = 
3.1 Hz, J = 11.5 Hz, 1H), 5.91 (s, 1H), 7.23 (d, J = 2.2 Hz, 1H), 7.42 (t, J = 7.7 Hz, 1H), 7.61 
(d, J = 7.4 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 8.82 (s, 1H), 10.08 (s, 1H). 
13
C NMR (100 MHz, 
CDCl3)  38.4 (CH2), 38.8 (CH2), 38.9 (CH2), 39.2 (CH3), 41.0 (CH2), 45.0 (CH2), 57.8 (CH), 
65.8 (Cq), 94.6 (CH), 119.8 (CH), 126.3 (CH), 129.3 (CH), 131.4 (CH), 133.2 (Cq), 133.3 
(Cq), 136.0 (Cq), 148.5 (Cq), 153.5 (Cq), 166.3 (Cq). HRMS (ESI) calc. for 
C19H21N5O2S2Na [M+Na]
+
: 438.1034, found: 438.1025. 
8.1.23. cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(1-
methyl-1H-pyrazol-3-yl)urea 26. 
Compound 26 was prepared following the general procedure A from the amine 9 and 1-
methyl-1H-pyrazole-3-carboxylic acid after purification by flash chromatography 
(CH2Cl2/MeOH 99/1) as a yellow solid in 81% yield. m.p. 196-198 °C. IR ( ATR-Diamond, 
cm
-1
) ν  1686, 1625, 1538, 1482-1421, 1316, 1284, 751. 1H NMR (400 MHz, CDCl3)  1.06 
(q, J = 12.0 Hz, 1H), 1.27-1.39 (m, 1H), 2.21 (d, J = 12.0 Hz, 1H), 2.97-3.08 (m, 2H), 3.35 (s, 
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3H), 3.55-3.60 (m, 1H), 3.87 (s, 3H), 4.56-4.60 (m, 2H), 5.84 (s, 1H), 7.27 (d, J = 2.2 Hz, 
1H), 7.45 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.62 (d, J = 7.5 Hz, 1H), 7.98 (s, 1H), 8.04 (d, J = 
8.0 Hz, 1H), 10.06 (s, 1H). 
13
C NMR (100 MHz, CDCl3)  30.3 (CH2), 35.7 (CH2), 37.0 
(CH2), 38.8 (CH3), 55.7 (CH3), 56.9 (CH), 77.2 (CH), 94.1 (CH), 119.5 (CH), 125.0 (CH), 
129.2 (CH), 131.5 (CH), 133.2 (Cq), 133.3 (Cq), 135.2 (Cq), 148.2 (Cq), 152.8 (Cq), 166.0 
(Cq). HRMS (ESI) calc. for C18H21N5O3Na [M+Na]
+
: 378.1542, found: 378.1542. 
8.1.24. 1-(5-Methylpyrazin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a] 
isoindole-2,2'-[1,3]dithiolan]-10-yl)urea 27. 
Compound 27 was prepared following the general procedure A from the amine 8 and 5-
methylpyrazine-2-carboxylic acid after purification by flash chromatography (CH2Cl2/ MeOH 
99/1) as a white solid in 85% yield. m.p. > 260 °C. IR ( ATR-Diamond, cm
-1
) ν  2977, 1688, 
1621, 1586, 1414, 1332, 1288, 753.
1
H NMR (400 MHz, DMSO-d6)  1.61 (t, J = 12.2 Hz, 
1H), 1.93 (td, J = 5.0 Hz, J = 12.2 Hz, 1H), 2.12 (d, J = 12.5 Hz, 1H), 2.43 (s, 3H), 2.87 (d, J
= 12.5 Hz, 1H), 3.14 (t, J = 12.2 Hz, 1H), 3.29-3.35 (m, 3H), 3.39-3.44 (m, 1H), 4.32 (dd, J = 
2.8 Hz, J = 12.2 Hz, 1H), 4.75 (dd, J = 2.8 Hz, J = 12.2 Hz, 1H), 7.42-7.50 (m, 2H), 8.06 (d, J
= 7.5 Hz, 1H), 8.27 (s, 1H), 8.73 (s, 1H), 10.04 (s, 2H). 
13
C NMR (100 MHz, DMSO-d6) 
20.2 (CH3), 37.8 (CH2), 38.2 (CH2), 38.7 (CH2), 40.5 (CH2), 41.0 (CH2), 56.9 (CH), 65.6 
(Cq), 118.2 (CH), 124.0 (CH), 129.1 (CH), 132.8 (Cq), 133.5 (Cq), 134.3 (CH), 134.6 (Cq), 
139.7 (CH), 146.0 (Cq), 146.9 (Cq), 151.8 (Cq), 164.7 (Cq). HRMS (ESI) calc. for 
C20H22N5O2S2 [M+H]
+
: 428.1215, found: 428.1229. 
8.1.25. cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(5-
methylpyrazin-2-yl)urea 28. 
Compound 28 was prepared following the general procedure A from the amine 9 and 5-
methylpyrazine-2-carboxylic acid after purification by flash chromatography (CH2Cl2/ MeOH 
99/1) as a yellow solid in 76% yield. m.p. 140-142 °C. IR ( ATR-Diamond, cm
-1
) ν  1688, 
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1598, 1554, 1484, 1438, 1344, 1291, 753. 
1
H NMR (400 MHz, CDCl3)  1.06 (q, J = 12.0 Hz, 
1H), 1.30-1.40 (m, 1H), 2.22 (d, J = 12.5 Hz, 1H), 2.54 (s, 3H), 2.96-3.06 (m, 2H), 3.38 (s, 
3H), 3.53-3.61 (m, 1H), 4.53-4.62 (m, 2H), 7.49 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.66 (d, J = 
7.5 Hz, 1H), 8.02 (s, 1H), 8.11 (d, J = 8.0 Hz, 1H), 8.42 (s, 1H), 9.80 (s, 1H), 11.16 (s, 1H). 
13
C NMR (100 MHz, CDCl3)  20.6 (CH3), 30.5 (CH2), 35.7 (CH2), 37.1 (CH2), 55.9 (CH3), 
56.9 (CH), 77.3 (CH), 120.0 (CH), 124.6 (CH), 129.5 (CH), 132.6 (Cq), 133.3 (Cq), 135.0 
(Cq), 135.1 (CH), 137.7 (CH), 146.6 (Cq), 146.7 (Cq), 153.5 (Cq), 165.9 (Cq). HRMS (ESI) 
calc. for C19H22N5O3 [M+H]
+
: 368.1723, found: 368.1722. 
8.1.26. cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-
methylpyridin-2-yl)urea 29. 
Compound 29 was prepared following the general procedure A from the amine 9 and 4-
methylpicolinic acid after purification by flash chromatography (CH2Cl2/MeOH 99/1) as a 
yellow solid in 76% yield. m.p. 218-220 °C. IR ( ATR-Diamond, cm
-1
) ν  1690, 1619, 1573, 
1481-1439, 1310, 1293, 752. 
1
H NMR (400 MHz, DMSO-d6)  0.75 (q, J = 12.0 Hz, 1H), 
1.08-1.19 (m, 1H), 2.14 (d, J = 12.0 Hz, 1H), 2.30 (s, 3H), 2.99 (d, J = 12.0 Hz, 1H), 3.10 (td, 
J = 3.2 Hz, J = 13.2 Hz, 1H), 3.25 (s, 3H), 3.69-3.77 (m, 1H), 4.29 (dd, J = 3.2 Hz, J = 13.2 
Hz, 1H), 4.70 (dd, J = 3.2 Hz, J = 12.0 Hz, 1H), 6.92 (d, J = 5.2 Hz, 1H), 7.08 (s, 1H), 7.37 
(d, J = 7.5 Hz, 1H), 7.46 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 8.20 (d, J = 5.2 Hz, 1H), 8.26 (d, J
= 8.0 Hz, 1H), 9.86 (s, 1H), 11.43 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  20.8 (CH3), 
30.7 (CH2), 35.2 (CH2), 36.5 (CH2), 55.2 (CH3), 55.8 (CH), 76.3 (CH), 112.1 (CH), 117.4 
(CH), 118.8 (CH), 122.2 (CH), 129.1 (CH), 132.7 (Cq), 133.9 (Cq), 134.0 (Cq), 145.6 (CH), 
150.0 (Cq), 152.2 (Cq), 152.9 (Cq), 164.7 (Cq). HRMS (ESI) calc. for C20H23N4O3 [M+H]
+
: 
367.1770, found: 367.1761. 
8.1.27. (6-Bromopyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoin-
dole-2,2'-[1,3]dithiolan]-10-yl)urea 30. 
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Compound 30 was obtained following the general procedure A from the amine 8 and 6-
bromopicolinic acid after purification by flash chromatography (CH2Cl2/MeOH 99/1) as a 
yellow solid in 57% yield. m.p. 168-170 °C. IR ( ATR-Diamond, cm
-1
) ν  1654, 1565, 1530, 
1486, 1430, 786.
1
H NMR (400 MHz, CDCl3)  1.66 (t, J = 12.0 Hz, 1H), 2.03 (td, J = 5.0 Hz, 
J = 13.4, 1H), 2.18 (d, J = 13.5 Hz, 1H), 2.85 (dd, J = 1.9 Hz, J = 10.0 Hz, 1H), 3.09-3.38 (m, 
5H), 4.55 (dd, J = 3.7 Hz, J = 13.8 Hz, 1H), 4.97 (dd, J = 3.3 Hz, J = 11.5 Hz, 1H), 7.14 (d, J
= 7.7 Hz, 2H), 7.51 (td, J = 5.7 Hz, J = 7.8 Hz, 2H), 7.72 (dd, J = 7.6 Hz, J = 13.4 Hz, 2H), 
9.91 (s, 1H), 10.88 (s, 1H). 
13
C NMR (100 MHz, CDCl3)  38.6 (CH2), 38.9 (CH2), 39.1 
(CH2), 41.0 (CH2), 45.2 (CH2), 58.3 (CH), 65.6 (Cq), 111.2 (CH), 121.0 (CH), 121.4 (CH), 
127.3 (CH), 129.4 (CH), 132.4 (Cq), 133.7 (Cq), 137.3 (Cq), 138.3 (Cq), 140.9 (CH), 153.1 
(Cq), 153.6 (Cq), 166.1 (Cq). HRMS (ESI) calc. for C20H19N4O2S2BrNa [M+Na]
+
: 513.0031, 
found: 513.0014. 
8.1.28. (5-Bromopyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoin-
dole-2,2'-[1,3]dithiolan]-10-yl)urea 31. 
Compound 31 was obtained following the general procedure A from the amine 8 and 5-
bromopicolinic acid after purification by flash chromatography (CH2Cl2/MeOH 99/1) as a 
yellow solid in 82% yield. m.p. 240-242 °C. IR ( ATR-Diamond, cm
-1
) ν  1700, 1551, 1481, 
1430, 1367, 1240, 1048, 759. 
1
H NMR (400 MHz, DMSO-d6)  1.66 (t, J = 12.0 Hz, 1H), 
1.95 (td, J = 5.0 Hz, J = 13.0 Hz, 1H), 2.15 (d, J = 13.0 Hz, 1H), 2.92 (d, J = 11.6 Hz, 1H), 
3.17 (td, J = 3.2 Hz, J = 13.3 Hz, 1H), 3.27-3.50 (m, 4H), 4.34 (dd, J = 3.2 Hz, J = 13.5 Hz, 
1H), 4.78 (dd, J = 3.3 Hz, J = 11.6 Hz, 1H), 7.33 (d, J = 8.9 Hz, 1H), 7.43 (d, J = 6.8 Hz, 1H), 
7.49 (t, J = 7.8 Hz, 1H), 8.01 (dd, J = 2.5 Hz, J = 8.9 Hz, 1H), 8.17 (d, J = 7.8 Hz, 1H), 8.57 
(d, J = 2.4 Hz, 1H), 10.10 (s, 1H), 10.69 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  37.7 
(CH2), 38.2 (CH2), 38.8 (CH2), 40.7 (CH2), 44.0 (CH2), 56.9 (CH), 65.7 (Cq), 111.4 (Cq), 
114.0 (CH), 118.0 (CH), 123.6 (CH), 129.1 (CH), 132.7 (Cq), 133.6 (Cq), 134.2 (Cq), 141.3 
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(CH), 147.1 (CH), 151.8 (2 Cq), 164.7 (Cq). HRMS (ESI) calc. for C20H19N4O2S2BrNa 
[M+Na]
+
: 513.0031, found: 513.0016. 
8.1.29. General procedure B: Preparation of the ketones 32-36. 
The chosen acetal (0.52 mmol) and a solution of hydrochloric acid 10% (2 mL) in 
acetone (4 mL) was refluxed for 3 h. After cooling, acetone was removed under reduced 
pressure. The resulting solid was filtered, washed with water (2 mL) and dried to give the 
corresponding ketones. 
8.1.30. 1-(2,6-Dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(pyridin-2-yl) 
urea 32. 
Compound 32 was obtained following the general procedure B from compound 11 as a 
white solid in 98% yield. m.p. 253-255 °C. IR ( ATR-Diamond, cm
-1
) ν  1692, 1623, 1568, 
1479, 1457, 1421, 1309, 1243, 751. 
1
H NMR (400 MHz, DMSO-d6)  2.34 (t, J = 12.0 Hz, 
1H), 2.38-2.45 (m, 1H), 2.57-2.66 (m, 1H), 3.26 (dd, J = 2.8 Hz, J = 13.0 Hz, 1H), 3.49 (td, J
= 4.4 Hz, J = 12.6 Hz, 1H), 4.47-4.50 (m, 1H), 5.08 (dd, J = 3.9 Hz, J = 11.9 Hz, 1H), 7.10 
(dd, J = 5.4 Hz, J = 6.8 Hz, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.45 (d, J = 6.8 Hz, 1H), 7.51 (t, J = 
7.7 Hz, 1H), 7.76-7.85 (m, 1H), 8.30 (d, J = 8.3 Hz, 1H), 8.34-8.40 (m, 1H), 9.99 (s, 1H), 
11.26 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  36.6 (CH2), 39.0 (CH2), 44.0 (CH2), 56.0 
(CH), 112.2 (CH), 117.5 (CH), 117.6 (CH), 122.7 (CH), 129.4 (CH), 132.5 (Cq), 133.7 (Cq), 
134.0 (Cq), 139.1 (CH), 146.2 (CH), 152.1 (Cq), 152.8 (Cq), 165.3 (Cq), 206.3 (Cq). HRMS 
(ESI) calc. for C18H17N4O3 [M+H]
+
: 337.1301, found: 337.1294. 
8.1.31. 1-(2,6-Dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(pyrazin-2-yl) 
urea 33. 
Compound 33 was obtained following the general procedure B from compound 14 as 
beige solid in 95% yield. m.p. > 260 °C. IR (ATR-Diamond, cm
-1
) ν  1689, 1660, 1569, 1502, 
1477, 1430, 1304, 1143, 1065.
1
H NMR (400 MHz, DMSO-d6)  2.31 (dd, J = 2.7 Hz, J = 
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13.5 Hz, 1H), 2.37-2.44 (m, 1H), 2.57-2.67 (m, 1H), 3.17 (dd, J = 2.7 Hz, J = 13.5 Hz, 1H), 
3.48 (td, J = 4.4 Hz, J = 12.8 Hz, 1H), 4.44-4.49 (m, 1H), 5.05 (dd, J = 3.9 Hz, J = 11.9 Hz, 
1H), 7.48 (dd, J = 1.2 Hz, J = 7.7 Hz, 1H), 7.53 (t, J = 7.7 Hz, 1H), 8.18 (dd, J = 0.9 Hz, J = 
7.5 Hz, 1H), 8.32 (d, J = 2.7 Hz, 1H), 8.35-8.37 (m, 1H), 8.90 (d, J = 1.2 Hz, 1H), 9.86 (s, 
1H), 10.12 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  36.6 (CH2), 39.0 (CH2), 43.9 (CH2), 
56.0 (CH), 118.1 (CH), 123.4 (CH), 129.4 (CH), 132.6 (Cq), 133.5 (Cq), 134.4 (Cq), 135.5 
(CH), 137.9 (CH), 141.0 (CH), 149.1 (Cq), 151.7 (Cq), 165.2 (Cq), 206.3 (Cq). HRMS (ESI) 
calc. for C17H15N5O3Na [M+Na]
+
: 360.1073, found: 360.1078. 
8.1.32. 1-(2,6-Dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(6-methyl- 
pyridin-2-yl)urea 34. 
Compound 34 was obtained following the general procedure B from compound 17 as 
white solid in 79% yield. m.p. 226-228 °C. IR ( ATR-Diamond, cm
-1
) ν  1683, 1621, 1566, 
1467-1435, 1323, 1287, 752.
1
H NMR (400 MHz, DMSO-d6)  2.37 (t, J = 12.5 Hz, 1H), 2.44 
(s, 3H), 2.54-2.68 (m, 1H), 3.11 (dd, J = 2.5 Hz, J = 12.8 Hz, 1H), 3.17 (d, J = 5.0 Hz, 1H), 
3.45 (td, J = 5.0 Hz, J = 12.8 Hz, 1H), 4.48 (dd, J = 2.8 Hz, J = 12.5 Hz, 1H), 5.08 (dd, J = 
2.8 Hz, J = 12.5 Hz, 1H), 6.91 (d, J = 7.5 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 7.45-7.55 (m, 
2H), 7.66 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 8.18 (d, J = 7.5 Hz, 1H), 9.84 (s, 1H), 10.70 (s, 
1H). 
13
C NMR (100 MHz, DMSO-d6)  23.6 (CH3), 36.6 (CH2), 39.0 (CH2), 43.7 (CH2), 56.1 
(CH), 109.0 (CH), 116.9 (CH), 118.0 (CH), 123.9 (CH), 129.3 (CH), 132.5 (Cq), 133.8 (Cq), 
134.4 (Cq), 139.2 (CH), 152.1 (Cq), 152.3 (Cq), 155.5 (Cq), 165.3 (Cq), 206.4 (Cq). HRMS 
(ESI) calc. for C19H19N4O3 [M+H]
+
: 351.1452, found: 351.1451. 
8.1.33. 1-(2,6-Dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-methoxy- 
quinolin-2-yl)urea 35. 
Compound 35 was obtained following the general procedure B from compound 20 as 
white solid in 83% yield. m.p. 223-225 °C. IR ( ATR-Diamond, cm
-1
) ν  2976, 1683, 1621, 
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1558, 1469, 1435, 1329, 1289, 751.
1
H NMR (400 MHz, DMSO-d6)  2.29 (t, J = 12.5 Hz, 
1H), 2.41 (d, J = 12.5 Hz, 1H), 2.53-2.62 (m, 1H), 3.20 (d, J = 12.8 Hz, 1H), 3.50 (td, J = 2.5 
Hz, J = 12.8 Hz, 1H), 4.13 (s, 3H), 4.44 (dd, J = 2.8 Hz, J = 12.8 Hz, 1H), 5.18 (dd, J = 2.8 
Hz, J = 12.5 Hz, 1H), 7.02 (s, 1H), 7.55-7.59 (m, 3H), 7.82 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 
8.00-8.11 (m, 3H), 10.99 (s, 1H), 11.32 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  36.5 
(CH2), 39.0 (CH2), 43.6 (CH2), 56.1 (CH3), 57.1 (CH), 92.1 (CH), 117.6 (Cq), 119.0 (CH), 
122.0 (CH), 122.8 (Cq), 124.9 (CH), 125.6 (CH), 129.4 (2 x CH), 132.4 (CH), 132.7 (Cq), 
132.8 (Cq), 135.8 (Cq), 152.0 (Cq), 152.3 (Cq), 165.1 (Cq), 165.3 (Cq), 205.7 (Cq). HRMS 
(ESI) calc. for C23H21N4O4 [M+H]
+
: 417.1563, found: 417.1571. 
8.1.34. 1-(2,6-Dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(3-methyl- 
pyridin-2-yl)urea 36. 
Compound 36 was obtained following the general procedure B from compound 23 as 
white solid in 85% yield. m.p. > 260 °C. IR ( ATR-Diamond, cm
-1
) ν  1684, 1621, 1559, 
1479, 1434, 1414, 1329, 1289, 751.
1
H NMR (400 MHz, DMSO-d6)  2.22 (t, J = 12.5 Hz, 
1H), 2.40 (d, J = 12.8 Hz, 1H), 2.49-2.60 (m, 4H), 3.33-3.38 (m, 1H), 3.47 (td, J = 2.5 Hz, J = 
12.8 Hz, 1H), 4.40-4.46 (m, 1H), 5.20 (dd, J = 2.5 Hz, J = 12.5 Hz, 1H), 7.36 (dd, J = 5.2 Hz, 
J = 7.5 Hz, 1H), 7.52-7.58 (m, 2H), 8.04 (d, J = 7.5 Hz, 1H), 8.16 (d, J = 7.5 Hz, 1H), 8.28 (d, 
J = 5.2 Hz, 1H), 10.91 (s, 1H), 11.49 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  17.9 (CH3), 
36.9 (CH2), 39.4 (CH2), 44.1 (CH2), 56.6 (CH), 118.8 (CH), 119.5 (CH), 124.7 (CH), 125.3 
(Cq), 129.9 (CH), 132.9 (Cq), 133.3 (Cq), 136.1 (Cq), 137.1 (CH), 145.5 (CH), 148.4 (Cq), 
153.2 (Cq), 165.5 (Cq), 206.3 (Cq). HRMS (ESI) calc. for C19H19N4O3 [M+H]
+
: 351.1452, 
found : 351.1451. 
8.1.35. General procedure C: Synthesis of alcohols 37-41. 
At -20 °C, to a solution of ketone (0.2 mmol) in a mixture THF/MeOH 1/2 (6 mL) was 
added portionwise NaBH4 (15 mg, 0.4 mmol, 2.0 eq.). The mixture was stirred at this 
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temperature for 30 min. and the temperature was then allowed to rise to 0-5 °C for 2 h. Water 
(10 mL) was added, and the aqueous phase was extracted first with CH2Cl2 (2 x 10 mL) and 
then with EtOAc (2 x 10 mL). The combined organic layers were dried over MgSO4, filtered 
and concentrated under reduced pressure.  
8.1.36. cis-1-(2-Hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-
(pyridin-2-yl)urea 37. 
Compound 37 was obtained following the general procedure C from compound 32 after 
purification by flash chromatography (CH2Cl2/MeOH 93/7) as a white solid in 76% yield. 
m.p. 218-220 °C. IR ( ATR-Diamond, cm
-1
) ν  3217, 1695, 1562, 1512- 1478-1430, 1309. 1H 
NMR (400 MHz, DMSO-d6)  0.77 (q, J = 12.0 Hz, 1H), 1.10-1.28 (m, 1H), 1.95 (d, J = 11.7 
Hz, 1H), 2.89 (d, J = 11.7 Hz, 1H), 3.08 (td, J = 4.1 Hz, J = 12.0 Hz, 1H), 3.60 (s, 1H), 3.96 
(t, J = 10.7 Hz, 1H), 4.24 (dd, J = 4.1 Hz, J = 13.2 Hz, 1H), 4.69 (dd, J = 2.8 Hz, J = 11.8 Hz, 
1H), 7.04-7.13 (m, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.38 (d, J = 7.3 Hz, 1H), 7.46 (t, J = 7.7 Hz, 
1H), 7.81 (t, J = 7.3 Hz, 1H), 8.21 (d, J = 7.7 Hz, 1H), 8.32 (d, J = 4.5 Hz, 1H), 9.96 (s, 1H), 
11.21 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  34.5 (CH2), 36.6 (CH2), 38.7 (CH2), 56.0 
(CH), 66.7 (CH), 112.1 (CH), 117.5 (CH), 117.6 (CH), 122.6 (CH), 128.9 (CH), 132.7 (Cq), 
133.8 (Cq), 134.4 (Cq), 139.1 (CH), 146.2 (CH), 152.1 (Cq), 152.8 (Cq), 164.7 (Cq). HRMS 
(ESI) calc. for C18H19N4O3 [M+H]
+
: 339.1457, found: 339.1462. 
8.1.37. cis-1-(2-Hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-
(pyrazin-2-yl)urea 38. 
Compound 38 was obtained following the general procedure C from compound 33 after 
purification by flash chromatography (CH2Cl2/MeOH 96/4) as a white solid in 60% yield. 
m.p. 250-252 °C. IR ( ATR-Diamond, cm
-1
) ν 1694, 1671, 1622, 1568, 1545, 1500, 1485, 
1427, 1296, 1056.
1
H NMR (400 MHz, DMSO-d6)  0.75 (q, J = 11.8 Hz, 1H), 1.14-1.23 (m, 
1H), 1.94 (d, J = 12.1 Hz, 1H), 2.78 (d, J = 11.8 Hz, 1H), 3.07 (td, J = 3.1 Hz, J = 13.2 Hz, 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
1H), 3.88-3.95 (m, 1H), 4.25 (dd, J = 3.9 Hz, J = 13.2 Hz, 1H), 4.65 (dd, J = 3.1 Hz, J = 11.8 
Hz, 1H), 5.01 (d, J = 4.9 Hz, 1H), 7.42 (dd, J = 0.8 Hz, J = 7.4 Hz, 1H), 7.48 (t, J = 7.7 Hz, 
1H), 8.10 (dd, J = 0.6 Hz, J = 7.7 Hz, 1H), 8.31 (d, J = 2.7 Hz, 1H), 8.32-8.38 (m, 1H), 8.94 
(d, J = 1.2 Hz, 1H), 9.85 (s, 1H), 10.08 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  34.4 (CH2), 
36.6 (CH2), 38.7 (CH2), 56.0 (CH), 66.7 (CH), 118.1 (CH), 123.3 (CH), 129.0 (CH), 132.8 
(Cq), 133.4 (Cq), 135.0 (Cq), 135.4 (CH), 137.9 (CH), 141.1 (CH), 149.2 (Cq), 151.7 (Cq), 
164.6 (Cq). HRMS (ESI) calc. for C17H17N5O3Na [M+Na]
+
: 362.1229, found: 362.1223. 
8.1.38. cis-1-(2-hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(6-
methylpyridin-2-yl)urea 39.
Compound 39 was obtained following the general procedure C from compound 34 after 
purification by flash chromatography (CH2Cl2/MeOH 99/1) as a white solid in 80% yield. 
m.p. 240-242 °C. IR ( ATR-Diamond, cm
-1
) ν 3143, 1685, 1589, 1508, 1484, 1424, 1270. 1H 
NMR (400 MHz, DMSO-d6)  0.76 (q, J = 12.5 Hz, 1H), 1.11-1.25 (m, 1H), 1.94 (d, J = 12.5 
Hz, 1H), 2.51 (s, 3H), 2.76 (d, J = 12.5 Hz, 1H), 3.07 (td, J = 2.5 Hz, J = 12.8 Hz, 1H), 3.82-
3.93 (m, 1H), 4.26 (dd, J = 2.8 Hz, J = 12.2 Hz, 1H), 4.71 (dd, J = 2.8 Hz, J = 12.2 Hz, 1H), 
5.01 (d, J = 5.0 Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 7.16 (d, J = 8.2 Hz, 1H), 7.39-7.51 (m, 2H), 
7.67 (dd, J = 7.5 Hz, J = 8.2 Hz, 1H), 8.17 (d, J = 7.5 Hz, 1H), 9.84 (s, 1H), 10.75 (s, 1H). 
13
C 
NMR (100 MHz, DMSO-d6)  23.8 (CH3), 34.4 (CH2), 36.6 (CH2), 38.4 (CH2), 56.1 (CH), 
66.8 (CH), 108.9 (CH), 116.8 (CH), 117.7 (CH), 123.6 (CH), 128.8 (CH), 132.7 (Cq), 133.7 
(Cq), 134.7 (Cq), 139.1 (CH), 152.2 (Cq), 152.3 (Cq), 155.4 (Cq), 164.7 (Cq). HRMS (ESI) 
calc. for C19H21N4O3 [M+H]
+
: 353.1614, found: 353.1619. 
8.1.39. cis-1-(2-hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-
methoxyquinolin-2-yl)urea 40. 
Compound 40 was obtained following the general procedure C from compound 35 after 
purification by flash chromatography (CH2Cl2/MeOH 99/1) as a white solid in 82% yield. 
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m.p. > 260 °C. IR ( ATR-Diamond, cm
-1
) ν 2977, 1686, 1585, 1512, 1479, 1414, 1289. 1H 
NMR (250 MHz, DMSO-d6)  0.76 (q, J = 12.5 Hz, 1H), 1.04-1.21 (m, 1H), 1.93 (d, J = 12.5 
Hz, 1H), 2.79 (d, J = 12.5 Hz, 1H), 3.14 (td, J = 2.8 Hz, J = 12.5 Hz, 1H), 3.77-3.90 (m, 1H), 
4.02 (s, 3H), 4.26 (dd, J = 2.8 Hz, J = 12.5 Hz, 1H), 4.82-4.91 (m, 2H), 6.87 (s, 1H), 7.42-
7.53 (m, 3H), 7.73 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 8.03 (d, J = 8.0 
Hz, 1H), 8.21 (d, J = 7.5 Hz, 1H), 10.16 (s, 1H), 11.95 (s, 1H). 
13
C NMR (63 MHz, DMSO-
d6)  34.5 (CH2), 36.6 (CH2), 38.1 (CH2), 56.1 (CH3), 56.2 (CH), 66.7 (CH), 91.9 (CH), 117.9 
(CH), 118.1 (Cq), 121.4 (CH), 123.8 (CH), 124.0 (CH), 126.1 (CH), 128.9 (CH), 130.8 (CH), 
132.8 (Cq), 133.5 (Cq), 135.0 (Cq), 145.7 (Cq), 152.3 (Cq), 153.7 (Cq), 163.0 (Cq), 164.7 
(Cq). HRMS (ESI) calc. for C23H23N4O4 [M+H]
+
: 419.1719, found: 419.1728. 
8.1.40. cis-1-(2-Hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl) -3-(3-
methylpyridin-2-yl)urea 41. 
Compound 41 was obtained following the general procedure C from compound 36 after 
purification by flash chromatography (CH2Cl2/MeOH 99/1) as a white solid in 82% yield. 
m.p. 204-206 °C. IR ( ATR-Diamond, cm
-1
) ν 2960, 1684, 1584, 1503, 1486-1420, 1262. 1H 
NMR (400 MHz, DMSO-d6)  0.80 (q, J = 12.5 Hz, 1H), 1.12-1.23 (m, 1H), 1.97 (d, J = 12.5 
Hz, 1H), 2.32 (s, 3H), 2.90 (d, J = 12.5 Hz, 1H), 3.08 (td, J = 2.5 Hz, J = 12.8 Hz, 1H), 3.95-
4.02 (m, 1H), 4.25 (dd, J = 2.8 Hz, J = 12.2 Hz, 1H), 4.70 (dd, J = 2.8 Hz, J = 12.2 Hz, 1H), 
5.01 (d, J = 5.0 Hz, 1H), 7.06 (dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.37 (d, J = 7.5 Hz, 1H), 7.47 
(dd, J = 7.5 Hz, J = 8.0 Hz, 1H), 7.67 (d, J = 7.5 Hz, 1H), 8.22 (d, J = 7.5 Hz, 1H), 8.27 (d, J
= 8.0 Hz, 1H), 8.87 (s, 1H), 12.32 (s, 1H). 
13
C NMR (100 MHz, DMSO-d6)  17.4 (CH3), 
31.1 (CH2), 35.0 (CH2), 37.1 (CH2), 56.5 (CH), 67.2 (CH), 117.9 (CH), 118.3 (CH), 121.8 
(Cq), 123.0 (CH), 129.5 (CH), 133.2 (Cq), 134.3 (Cq), 134.8 (Cq), 140.6 (CH), 143.5 (CH), 
151.6 (Cq), 152.8 (Cq), 165.2 (Cq). HRMS (ESI) calc. for C19H21N4O3 [M+H]
+
: 353.1614, 
found: 353.1616. 
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8.2. Kinase assay.  
Kinase activities were assayed in Buffer A or C, at 30 °C, at a final ATP concentration of 15 
µM. Blank values were subtracted and activities expressed in % of the maximal activity, i.e. 
in the absence of inhibitors. Controls were performed with appropriate dilutions of DMSO. 
The kinase peptide substrates were obtained from Proteogenix (Oberhausbergen, France). 
DYRK1A (human, recombinant, expressed in E. coli as a GST fusion protein) was purified by 
affinity chromatography on glutathione-agarose and assayed in buffer A (+ 0.5 mg BSA / mL) 
using Woodtide (KKISGRLSPIMTEQ) (1.5 µg / assay) as a substrate, in the presence of 15 
µM [γ-33P] ATP (3,000 Ci / mmol ; 10 mCi / mL) in a final volume of 30 µl.28 After 30 min 
incubation at 30 °C, the reaction was stopped by harvesting onto P81 phosphocellulose papers 
(Whatman) using a FilterMate harvester (Packard) and filters were washed in 1% phosphoric 
acid. Scintillation fluid was added and the radioactivity measured in a Packard counter. CDK5 
/ p25 (human, recombinant) was prepared as previously described [13]. Its kinase activity was 
assayed in buffer B, with 1 mg histone H1 / mL. GSK-3α/β (porcine brain, native) was 
assayed in Buffer A using a GSK3 specific substrate (GS-1: RRAAVPPSPSLSRHSSPH 
QSpEDEEE) (pS stands for phosphorylated serine) [14].  
8.3. Cell culture and survival assay.  
HuH7, CaCo-2, MDA-MB-231, HCT116, PC3, HaCaT and NCI-H727 cell lines were 
obtained from the ECACC collection. Skin diploid fibroblastic cells were provided by 
BIOPREDIC International Company (Rennes, France). Cells were grown according to 
ECACC recommendations. The toxicity test of the compounds on these cells was as follows: 
2.10
3
 cells/well for HCT116 cell line or 4.10
3
 cells/well for the other cell lines were seeded in 
96 well plates. 24h after cell seeding, cells were exposed to increasing concentrations of the 
compounds (0.1µM-0.3µM-0.9µM-2.7µM-8.3µM-25µM). After 48h of treatment, the cells 
were washed in PBS and fixed in cooled 90% ethanol/5% acetic acid for 20min. Then, the 
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nuclei were stained with Hoechst 3342 (Sigma). Image acquisition and analysis was 
performed using a Cellomics ArrayScan VTI/ HCS Reader (Thermo Scientific). The Ic50 
were determined using Xlfit software. 
8.4. Molecular modeling.  
Hardware and software: molecular modelling studies were performed with the 
Schrodinger Molecular Modelling Suite 2014 update 3 [15] with Maestro, the interface 
piloting the diverse modules. Glide was used to dock ligands. Analysis and visualization tasks 
were performed with MOE software [16].  
Structure preparation: crystal structures were retrieved from the protein data bank: 
GSK3b with the PDB code 1J1B [17], CDK5 with the PDB code 4AU8 [18] and DYRK1A 
with the PDB code 4MQ1 [19]. Subunit A was conserved regarding the three structures which 
were next prepared using the Protein Preparation Wizard workflow of the Schrodinger 
Molecular Modelling Suite. Proteins were preprocessed (hydrogen atoms added, incomplete 
residues filled), bond orders and connections of ligands were manually corrected. An 
exhaustive sampling was conducted regarding hydrogen bond assignment and the complex 
was finally refined by a minimization stage with a constraint to converge to a structure with 
an RMSD of 0.3 _A (OPLS2005 force field), essentially in order to remove steric clashes. 
Ligands, other than the one cocrystallized, were built within Marvin Sketch 5.8.0 [20] and 
were submitted to Corina [21], a 3D structure generator. Next 3D structures were submitted to 
the LigPrep module of the Schrodinger Molecular Modelling Suite in order to take into 
account tautomerization and ionization via the Epik module. The resulting structures became 
the starting point for docking simulations. Docking parameters: docking calculations were 
performed with extra precision. Ligand flexibility was taken into account and the option of 
sampling of ring conformation was activated. 
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Figure 1. Some examples of CDK5, GSK3 and DYRK1A inhibitors.
Figure 2. Binding mode representation of compound 29 in GSK3β (PDB entry 1J1B).
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Figure 1. Some examples of CDK5, GSK3 and DYRK1A inhibitors.
Scheme 1. Retrosynthetic scheme for the design of novel CDK5, GSK3 and DYRK1A valmerin inhibitors. 
Scheme 2. Reagents and conditions : i) 1,2-ethanedithiol (5.0 eq.), BF3.Et2O (5.0 eq.), CH2Cl2, r.t., 24 h, 86% ; 
ii) NaBH4 (2.0 eq.), THF/MeOH (1/2), -20 °C to r.t., 5 h, 86% (mixture of cis-6 and trans-6) ; iii) Ag2O (4.0 
eq.), CH3I (10.0 eq.), THF, 50 °C, 48 h, 61% (from 4); iv) SnCl2 (15.0 eq.), EtOH, r.t., 12 h, 8 80% or 10 82% ;
v) H2, Patm, Raney Ni, EtOH, r.t., 14 h, 95%. 
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Scheme 3. Reagents and conditions : i) a) Et3N (1.3 eq.), -10 °C, THF, 5 min. ; b) ClCO2Et (1.5 eq.), -10 °C, 
THF, 2 h ; c) NaN3 (1.7 eq.), -10 °C, H2O, 1 h ; d) toluene, reflux, 1 h ; ii) (Het)ArNCO, dioxane, 100 °C, 24 h ; 
iii) HCl 10%, acetone, reflux, 3 h; iv) NaBH4 (2.0 eq.), THF/MeOH (1/1), 0 °C-5 °C, 2 h. For yields see Table 1. 
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Table 1. Synthesis of Valmerins 11-41.  
Entry (Het)Ar R / R1 Product Yield
a
1 
a -OCH2CH2O- 11 78 % 
b -SCH2CH2S- 12 96 % 
c cis OCH3 13 81 % 
d =O 32 Obtained from 11, quant. 
e cis OH 37 Obtained from 32, 76 % 
2 
a -OCH2CH2O- 14 68 % 
b -SCH2CH2S- 15 90 % 
c cis OCH3 16 78 % 
d =O 33 Obtained from 14, 95% 
e cis OH 38 Obtained from 33, 60% 
3 
a -OCH2CH2O- 17 75 % 
b -SCH2CH2S- 18 78 % 
c cis OCH3 19 75 % 
d =O 34 Obtained from 17, 79% 
e cis OH 39 Obtained from 34, 80 % 
4 
a -OCH2CH2O- 20 72 % 
b -SCH2CH2S- 21 80 % 
c cis OCH3 22 80 % 
d =O 35 Obtained from 20, 83% 
e cis OH 40 Obtained from 35, 82% 
5 
a -OCH2CH2O- 23 72 % 
b cis OCH3 24 73 % 
c =O 36 Obtained from 23, 85 % 
d H / OH 41 Obtained from 36, 82% 
6 
a -SCH2CH2S- 25 68 % 
b cis OCH3 26 81 % 
7 
a -SCH2CH2S- 27 85 % 
b cis OCH3 28 76 % 
8 cis OCH3 29 76 % 
9 -SCH2CH2S- 30 57 % 
10 -SCH2CH2S- 31 82 % 
a 
Yields are indicated for isolated products. 
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Table 2. Kinase inhibitions of derivatives 11-41.  
Entry (Het)Ar R / R1 Product 
CDK5  
IC50 (µM) 
GSK3α/β 
IC50 (µM) 
Selectivity  
CDK5 / GSK3 
DYRK1A 
IC50 (µM) 
1 
a -OCH2CH2O- 11 11 0.7 
1.5 80 
b -SCH2CH2S- 12 0.24 0.033 
7.2 > 10 
c cis OCH3 13 0.55 0.081 
6.8 > 10 
d =O 32 1.6 0.23 6.3 25 
e cis OH 37 2.1 0.26 8.0 34 
2 
a -OCH2CH2O- 14 7.1 0.26 
27.3 93 
b -SCH2CH2S- 15 0.15 0.044 
3.4 > 10 
c cis OCH3 16 0.48 0.2 
2.4 > 10 
d =O 33 3.6 1.2 3.0 50 
e cis OH 38 0.084 0.032 2.6 > 10 
3 
a -OCH2CH2O- 17 > 10 0.92 > 10 > 10 
b -SCH2CH2S- 18 > 10 2 > 5 > 10 
c cis OCH3 19 4.3 0.32 13.4 > 10 
d =O 34 ND ND ND ND 
e cis OH 39 1.0 0.030 33.3 7.0 
4 
a  -OCH2CH2O- 20 > 10 1.0 > 10 > 10 
b -SCH2CH2S- 21 > 10 4 > 2.5 > 10 
c cis OCH3 22 8.5 0.18 47.5 > 10 
d =O 35 ND ND ND ND 
e cis OH 40 4.9 0.035 140 > 10 
5 
a -OCH2CH2O- 23 3.1 0.61 5.0 > 10 
b cis OCH3 24 1.1 0.25 4.4 > 10 
c =O 36  ND  ND  ND  ND 
d cis OH 41 0.63 0.16  6.2 
6 
a -SCH2CH2S- 25  10 1.9  5.2 > 10 
b cis OCH3 26 2.3 1.1 
2.0 > 10 
7 
a -SCH2CH2S- 27 0.22 0.055 4.0 > 10 
b cis OCH3 28 0.32 0.14 10.0 > 10 
8 cis OCH3 29 0.32 0.032 10.0 > 10 
9 -SCH2CH2S- 30 > 10 0.71 > 14.0 8.7 
10 -SCH2CH2S- 31 7.3 0.068 107.3  10 
Assays were performed in triplicate.  
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Figure 2. Binding mode representation of compound 29 in GSK3β (PDB entry 1J1B).
Table 3. Most potent Valmerins in cell line assays.  
Entry (Het)Ar R / R1 Product 
Human cell lines IC50 (µM) 
Huh7 Caco2 
MDA-
MB 231 
HCT 
116 
PC3 
NCI
H727 
1 ---- ---- Roscovitine 5 3 3 2 2 4 
2 -SCH2CH2S- 15 0.1 0.5 0.15 0.1 0.6 0.4 
3 -SCH2CH2S- 27 0.3 0.5 0.4 0.2 0.4 0.8 
4 cis OCH3 29 0.1 0.5 0.3 0.03 0.4 0.4 
Assays were performed in triplicate .  
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Advances in Tetrahydropyrido[1,2-a]isoindolone 
(Valmerins) Series: Potent Glycogen Synthase Kinase 3 and 
Cyclin Dependent Kinase 5 Inhibitors.
Rajâa Boulahjar,1 Aziz Ouach,1 Stéphane Bourg,1 Pascal Bonnet,1 Olivier Lozach,2 Laurent 
Meijer,2 Christiane Guguen-Guillouzo,3 Rémy Le Guevel,3 Saïd Lazar,4 Mohamed Akssira,4
Yves Troin,5 Gérald Guillaumet1,* and Sylvain Routier1,*
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Spectral data of representative compounds
10-Nitro-1,3,4,10b-tetrahydro-6H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dithiolan]-6-one 5.
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Cis-2-hydroxy-10-nitro-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one cis-6.
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Cis-2-methoxy-10-nitro-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one 7.
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10-Amino-1,3,4,10b-tetrahydro-6H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dithiolan]-6-one
8.
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Cis-10-amino-2-methoxy-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one 9.
-101234567891011121314
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10-Amino-1,3,4,10b-tetrahydro-6H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dioxolan]-6-one 
10.
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1-(6-Oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dioxolan]-10-yl)-3-
(pyridin-2-yl)urea 11.
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1-(6-Oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dithiolan]-10-yl)-3-
(pyridin-2-yl)urea 12.
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Cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(pyridin-2-
yl)urea 13.
-101234567891011121314
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1-(6-Oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dioxolan]-10-yl)-3-
(pyrazin-2-yl)urea 14.
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1-(6-Oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-[1,3]dithiolan]-10-yl)-3-
(pyrazin-2-yl)urea 15.
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Cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(pyrazin-2-
yl)urea 16.
-101234567891011121314
f1 (ppm)
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
1
.1
4
1
.0
8
1
.1
0
1
.0
7
1
.0
7
3
.1
8
1
.0
8
1
.1
3
1
.0
7
1
.0
8
1
.0
7
1
.0
0
1
.0
0
1
.0
0
1
.0
1
0
.9
6
1
.0
0
0
.7
6
7
0
.7
9
6
0
.8
2
5
0
.8
5
4
1
.1
3
7
1
.1
5
0
1
.1
6
8
1
.1
8
0
1
.1
9
6
1
.2
0
9
1
.2
2
7
1
.2
4
0
2
.1
8
5
2
.2
1
6
2
.5
5
9
2
.5
6
3
2
.9
6
0
3
.1
4
2
3
.1
5
0
3
.7
2
2
3
.7
3
1
3
.7
4
0
4
.3
2
6
4
.3
3
5
4
.3
5
9
4
.3
6
9
4
.7
1
1
4
.7
1
9
4
.7
4
0
4
.7
4
8
7
.4
6
3
7
.4
8
3
7
.5
2
2
7
.5
4
2
7
.5
6
1
8
.3
5
5
8
.3
6
2
8
.4
0
0
8
.4
0
4
9
.0
0
6
9
.0
0
9
9
.8
5
1
1
0
.1
3
7
16
-100102030405060708090100110120130140150160170180190200
f1 (ppm)
-5
0
5
10
15
20
25
30
35
40
45
50
3
0
.6
6
2
3
5
.2
7
8
3
6
.4
5
9
3
8
.8
9
4
3
9
.1
0
3
3
9
.3
1
1
3
9
.5
2
0
3
9
.7
2
9
3
9
.9
3
7
4
0
.1
4
6
5
5
.1
9
6
5
5
.8
3
5
7
6
.2
7
1
1
1
7
.9
9
5
1
2
3
.0
8
4
1
2
9
.0
5
8
1
3
2
.8
3
7
1
3
3
.5
2
0
1
3
4
.5
3
6
1
3
5
.4
6
6
1
3
7
.9
0
6
1
4
1
.1
1
3
1
4
9
.2
0
1
1
5
1
.6
7
8
1
6
4
.5
9
1
16
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
1-(6-Methylpyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-
2,2'-[1,3]dioxolan]-10-yl)urea 17.
-101234567891011121314
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1-(6-Methylpyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-
2,2'-[1,3]dithiolan]-10-yl)urea 18.
-101234567891011121314
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ACCEPTED MANUSCRIPT
Cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(6-methyl-
pyridin-2-yl)urea 19.
-101234567891011121314
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ACCEPTED MANUSCRIPT
1-(4-Methoxyquinolin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a] isoindole-
2,2'-[1,3]dioxolan]-10-yl)urea 20.
-101234567891011121314
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ACCEPTED MANUSCRIPT
1-(4-Methoxyquinolin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a] soindole-
2,2'-[1,3]dithiolan]-10-yl)urea 21.
-101234567891011121314
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ACCEPTED MANUSCRIPT
Cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-
methoxyquinolin-2-yl)urea 22.
-101234567891011121314
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ACCEPTED MANUSCRIPT
1-(3-Methylpyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a] isoindole-
2,2'-[1,3]dioxolan]-10-yl)urea 23.
-101234567891011121314
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cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(3-
methylpyridin-2-yl)urea 24.
-101234567891011121314
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1-(1-methyl-1H-pyrazol-3-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]
isoindole-2,2'-[1,3]dithiolan]-10-yl)urea 25.
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ACCEPTED MANUSCRIPT
Cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(1-methyl-
1H-pyrazol-3-yl)urea 26.
-101234567891011121314
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1-(5-Methylpyrazin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-
2,2'-[1,3]dithiolan]-10-yl)urea 27.
-101234567891011121314
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ACCEPTED MANUSCRIPT
Cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(5-
methylpyrazin-2-yl)urea 28.
-101234567891011121314
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ACCEPTED MANUSCRIPT
Cis-1-(2-Methoxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-
methylpyridin-2-yl)urea 29.
-101234567891011121314
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(6-Bromopyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-
[1,3]dithiolan]-10-yl)urea 30.
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(5-Bromopyridin-2-yl)-3-(6-oxo-3,4,6,10b-tetrahydro-1H-spiro[pyrido[2,1-a]isoindole-2,2'-
[1,3]dithiolan]-10-yl)urea 31.
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1-(2,6-Dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(pyridin-2-yl)urea 32.
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1-(2,6-Dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(pyrazin-2-yl)urea 33.
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1-(2,6-Dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(6-methyl- pyridin-2-
yl)urea 34.
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1-(2,6-dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-methoxyquinolin-2-
yl)urea 35.
-101234567891011121314
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1-(2,6-Dioxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(3-methylpyridin-2-
yl)urea 36.
-101234567891011121314
f1 (ppm)
-500
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
1
.0
0
1
.0
5
5
.0
1
1
.0
1
1
.0
3
1
.0
0
1
.0
1
1
.0
0
2
.0
3
1
.0
0
1
.0
0
1
.0
0
1
.0
1
1
.0
0
2
.1
8
2
2
.2
1
2
2
.2
1
7
2
.2
4
7
2
.3
8
4
2
.4
2
1
2
.5
0
0
2
.5
1
9
2
.5
3
9
2
.5
4
8
2
.5
5
6
2
.5
6
7
2
.5
7
5
2
.5
8
4
2
.6
0
3
3
.3
2
6
3
.3
3
5
3
.3
6
2
3
.3
7
1
3
.4
6
5
4
.4
2
1
4
.4
2
7
4
.4
3
5
4
.4
4
1
5
.1
7
8
5
.1
8
9
5
.2
0
7
5
.2
1
7
7
.3
5
1
7
.3
6
9
7
.3
8
5
7
.5
2
4
7
.5
3
9
7
.5
4
3
7
.5
4
7
7
.5
6
6
7
.5
8
4
8
.0
3
0
8
.0
4
8
8
.1
5
6
8
.1
7
4
8
.2
7
8
8
.2
9
1
1
0
.9
1
0
1
1
.4
8
8
36
0102030405060708090100110120130140150160170180190200210220230240
f1 (ppm)
-2000
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
13000
14000
15000
16000
17000
18000
19000
20000
21000
22000
1
7
.9
3
2
3
6
.9
5
0
3
8
.9
8
0
3
9
.3
1
4
3
9
.6
4
7
3
9
.9
8
1
4
0
.3
1
5
4
0
.6
4
8
4
0
.9
8
2
4
4
.1
5
7
5
6
.5
7
1
1
1
8
.7
9
7
1
1
9
.5
0
7
1
2
4
.7
4
9
1
2
5
.3
1
6
1
2
9
.9
1
8
1
3
2
.9
1
2
1
3
3
.3
3
5
1
3
6
.1
1
6
1
3
7
.0
6
4
1
4
5
.5
5
5
1
4
8
.4
6
6
1
5
3
.2
0
2
1
6
5
.5
6
5
2
0
6
.3
5
7
36
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Cis-1-(2-Hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(pyridin-2-
yl)urea 37.
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Cis-1-(2-Hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(pyrazin-2-
yl)urea 38.
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cis-1-(2-hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(6-
methylpyridin-2-yl)urea 39.
-101234567891011121314
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cis-1-(2-hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(4-
methoxyquinolin-2-yl)urea 40.
-101234567891011121314
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cis-1-(2-Hydroxy-6-oxo-1,2,3,4,6,10b-hexahydropyrido[2,1-a]isoindol-10-yl)-3-(3-
methylpyridin-2-yl)urea 41.
-101234567891011121314
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